APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 03
March 2009



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

29th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2009

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

29th EDITION

Cumulative Supplement 3

March 2009

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

29th EDITION

CUMULATIVE SUPPLEMENT 3
March 2009

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 28th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 29th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 30th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@cder.fda.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7500 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
DABUR ONCOLOGY PLC (DABUR ONCOLOGY PLC)	FRESENIUS KABI ONCOLOGY PLC (FRESENIUS KABI ONCOL)

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.fda.gov/cder/ob/default.htm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Annual Edition. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/cder/orange/obreadme.htm . The drug product text files are provided in eobzip.exe and eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not

previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2008	MAR 2009	JUN 2009	SEPT 2009
DRUG PRODUCTS LISTED	12751	12910		
SINGLE SOURCE	2433	2449		
	(19.1%)	(19.0%)		
MULTISOURCE	10229	10372		
	(80.2%)	(80.3%)		
THERAPEUTICALLY EQUIVALENT	10072	10216		
	(79.0%)	(79.1%)		
NOT THERAPEUTICALLY EQUIVALENT	157	156		
	(1.2%)	(1.2%)		
EXCEPTIONS[1]	89	89		
	(0.7%)	(0.7%)		
NEW MOLECULAR ENTITIES APPROVED	15	5		
NUMBER OF APPLICANTS	719	724		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

>D>	AA	SANDOZ	300MG;30MG	N81250	001	Jul 16, 1992	Mar	DISC
>A>		@	300MG;30MG	N81250	001	Jul 16, 1992	Mar	DISC
>D>	AA		300MG;60MG	N81249	001	Jul 16, 1992	Mar	DISC
>A>		@	300MG;60MG	N81249	001	Jul 16, 1992	Mar	DISC

TYLENOL W/ CODEINE NO. 4

>D>		@ ORTHO MCNEIL JANSSEN	300MG;60MG	N85055	004		Mar	CMFD
>A>	AA		300MG;60MG	N85055	004		Mar	CMFD

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

		@ MALLINCKRODT	500MG;5MG	N89006	001	Aug 09, 1985	Feb	CTNA

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

>D>	AA	SANDOZ	650MG;65MG	N89959	001	Jul 18, 1989	Mar	DISC
>A>		@	650MG;65MG	N89959	001	Jul 18, 1989	Mar	DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

>D>	AB	SANDOZ	650MG;100MG	N70443	001	Jan 23, 1986	Mar	DISC
>A>		@	650MG;100MG	N70443	001	Jan 23, 1986	Mar	DISC

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL

		@ ARMSTRONG PHARMS	0.09MG/INH	N72273	001	Aug 14, 1996	Jan	DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

	AN	HOLOPACK INTL	EQ 0.083% BASE	N77839	001	Dec 16, 2008	Jan	CAHN

TABLET; ORAL
ALBUTEROL SULFATE

>D>	AB	SANDOZ	EQ 2MG BASE	N72151	001	Dec 05, 1989	Mar	DISC
>A>		@	EQ 2MG BASE	N72151	001	Dec 05, 1989	Mar	DISC
>D>	AB		EQ 4MG BASE	N72152	001	Dec 05, 1989	Mar	DISC
>A>		@	EQ 4MG BASE	N72152	001	Dec 05, 1989	Mar	DISC

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

>D>	AB	SANDOZ	100MG	N70268	001	Dec 31, 1985	Mar	DISC
>A>		@	100MG	N70268	001	Dec 31, 1985	Mar	DISC
>D>	AB		300MG	N70269	001	Dec 31, 1985	Mar	DISC
>A>		@	300MG	N70269	001	Dec 31, 1985	Mar	DISC

AMILORIDE HYDROCHLORIDE

TABLET; ORAL
AMILORIDE HYDROCHLORIDE

	AB	+	PAR PHARM	5MG	N70346	001	Jan 22, 1986	Jan	CTEC
	AB		SIGMAPHARM LABS LLC	5MG	N79133	001	Jan 30, 2009	Jan	NEWA

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D>	AB		SANDOZ	EQ 5MG ANHYDROUS;50MG	N73357	001	Nov 27, 1991	Mar	DISC
>A>			@	EQ 5MG ANHYDROUS;50MG	N73357	001	Nov 27, 1991	Mar	DISC

AMINOCAPROIC ACID

TABLET; ORAL
AMICAR

			XANODYNE PHARM	1GM	N15197	002	Jun 24, 2004	Jan	NEWA

AMLODIPINE BESYLATE

TABLET; ORAL
AMLODIPINE BESYLATE

>A>	AB		GLENMARK GENERICS	EQ 2.5MG BASE	N78552	001	Apr 08, 2009	Mar	NEWA
>A>	AB			EQ 5MG BASE	N78552	002	Apr 08, 2009	Mar	NEWA
>A>	AB			EQ 10MG BASE	N78552	003	Apr 08, 2009	Mar	NEWA
	AB		SYNTHON PHARMS	EQ 2.5MG BASE	N77080	001	Jun 27, 2007	Jan	CAHN
	AB			EQ 5MG BASE	N77080	002	Jun 27, 2007	Jan	CAHN
	AB			EQ 10MG BASE	N77080	003	Jun 27, 2007	Jan	CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

	AB		APOTEX	250MG;EQ 125MG BASE	N65333	001	Feb 24, 2009	Feb	NEWA
	AB			500MG;EQ 125MG BASE	N65333	002	Feb 24, 2009	Feb	NEWA

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
APRACLONIDINE HYDROCHLORIDE

	AT		AKORN INC	EQ 0.5% BASE	N77764	001	Mar 12, 2009	Feb	NEWA

IOPIDINE

	AT	+	ALCON	EQ 0.5% BASE	N20258	001	Jul 30, 1993	Feb	CFTG

ARMODAFINIL

TABLET; ORAL
NUVIGIL

>D>			@ CEPHALON	100MG	N21875	002	Jun 15, 2007	Mar	CMFD
>A>				100MG	N21875	002	Mar 26, 2009	Mar	CMFD
>A>				200MG	N21875	005	Mar 26, 2009	Mar	NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

>D>	AB		SANDOZ	325MG;50MG;40MG	N86398	002	Apr 06, 1984	Mar	DISC
>A>			@	325MG;50MG;40MG	N86398	002	Apr 06, 1984	Mar	DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

		@	SOLCO HLTHCARE	385MG;30MG;25MG	N75141	001	May 29, 1998	Jan	CAHN

ORPHENGESIC FORTE

		@	SOLCO HLTHCARE	770MG;60MG;50MG	N75141	002	May 29, 1998	Jan	CAHN

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

		@	HOSPIRA	10MG/ML	N74740	001	Mar 28, 1997	Jan	DISC

ATRACURIUM BESYLATE PRESERVATIVE FREE

		@	HOSPIRA	10MG/ML	N74741	001	Mar 28, 1997	Jan	DISC

AZACITIDINE

INJECTABLE; IV-SC

VIDAZA

>A>		+	CELGENE	100MG/VIAL	N50794	001	May 19, 2004	Mar	CAHN
>D>		+	PHARMION LLC	100MG/VIAL	N50794	001	May 19, 2004	Mar	CAHN

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

>A>	AP		SAGENT STRIDES	EQ 500MG BASE/VIAL	N65506	001	Mar 24, 2009	Mar	NEWA

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

TACLONEX

>A>		+	LEO PHARM	0.064%;0.005%	N21852	001	Jan 09, 2006	Mar	CAHN
>D>		+	LEO PHARM PRODS	0.064%;0.005%	N21852	001	Jan 09, 2006	Mar	CAHN

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

>A>	AN		APOTEX	0.25MG/2ML	N78202	001	Mar 30, 2009	Mar	NEWA
>A>	AN			0.5MG/2ML	N78202	002	Mar 30, 2009	Mar	NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

>A>	AB1		WATSON LABS	100MG	N79095	001	Mar 24, 2009	Mar	NEWA
>A>	AB2			150MG	N79094	001	Mar 24, 2009	Mar	NEWA
>A>	AB1			150MG	N79095	002	Mar 24, 2009	Mar	NEWA
>A>	AB1			200MG	N79095	003	Mar 24, 2009	Mar	NEWA

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

	AB	+	BRISTOL MYERS SQUIBB	15MG	N18731	003	Apr 22, 1996	Feb	CRLD
		@		30MG	N18731	004	Apr 22, 1996	Feb	DISC

BUSPIRONE HYDROCHLORIDE

	AB		DR REDDYS LABS LTD	5MG	N78246	001	Feb 27, 2009	Feb	NEWA
	AB			10MG	N78246	002	Feb 27, 2009	Feb	NEWA
	AB			15MG	N78246	003	Feb 27, 2009	Feb	NEWA
	AB			30MG	N78246	004	Feb 27, 2009	Feb	NEWA

TABLET; ORAL
BUSPIRONE HYDROCHLORIDE

>D>	AB		SANDOZ	5MG	N75413	001	Mar 19, 2002	Mar	DISC
>A>			@	5MG	N75413	001	Mar 19, 2002	Mar	DISC
>D>	AB			10MG	N75413	002	Mar 19, 2002	Mar	DISC
>A>			@	10MG	N75413	002	Mar 19, 2002	Mar	DISC
>D>	AB			15MG	N75413	003	Mar 19, 2002	Mar	DISC
>A>			@	15MG	N75413	003	Mar 19, 2002	Mar	DISC

CALCITRIOL

CAPSULE; ORAL
ROCALTROL

>D>	AB		FONTUS PHARMS	0.25UGM	N18044	001		Mar	CAHN
>D>	AB	+		0.5UGM	N18044	002		Mar	CAHN
>A>	AB		VALIDUS PHARMS	0.25UGM	N18044	001		Mar	CAHN
>A>	AB	+		0.5UGM	N18044	002		Mar	CAHN

OINTMENT; TOPICAL
VECTICAL

		+	GALDERMA LABS LP	3UGM/GM	N22087	001	Jan 23, 2009	Jan	NEWA

SOLUTION; ORAL
ROCALTROL

>D>	AA	+	FONTUS PHARMS	1UGM/ML	N21068	001	Nov 20, 1998	Mar	CAHN
>A>	AA	+	VALIDUS PHARMS	1UGM/ML	N21068	001	Nov 20, 1998	Mar	CAHN

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL
CARBAMAZEPINE

	AB		TORRENT PHARMS	100MG	N75712	001	Jul 05, 2001	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL
>A> CARBAMAZEPINE

>A>	AB		TARO	100MG	N78115	001	Mar 31, 2009	Mar	NEWA
>A>	AB			200MG	N78115	002	Mar 31, 2009	Mar	NEWA
>A>	AB			400MG	N78115	003	Mar 31, 2009	Mar	NEWA

TEGRETOL-XR

>D>			NOVARTIS	100MG	N20234	001	Mar 25, 1996	Mar	CFTG
>A>	AB			100MG	N20234	001	Mar 25, 1996	Mar	CFTG
>D>				200MG	N20234	002	Mar 25, 1996	Mar	CFTG
>A>	AB			200MG	N20234	002	Mar 25, 1996	Mar	CFTG
>D>		+		400MG	N20234	003	Mar 25, 1996	Mar	CFTG
>A>	AB	+		400MG	N20234	003	Mar 25, 1996	Mar	CFTG

>D> CARBENICILLIN INDANYL SODIUM

>D> TABLET; ORAL
>D> GEOCILLIN

>D>		+	PFIZER	EQ 382MG BASE	N50435	001		Mar	DISC
>A>			@	EQ 382MG BASE	N50435	001		Mar	DISC

CARBIDOPA; LEVODOPA

TABLET; ORAL
CARBIDOPA AND LEVODOPA

>D>	AB		SANDOZ	10MG;100MG	N73586	001	Jun 29, 1995	Mar	DISC
>A>			@	10MG;100MG	N73586	001	Jun 29, 1995	Mar	DISC
>D>	AB			25MG;100MG	N73587	001	Jun 29, 1995	Mar	DISC
>A>			@	25MG;100MG	N73587	001	Jun 29, 1995	Mar	DISC
>D>	AB			25MG;250MG	N73620	001	Jun 29, 1995	Mar	DISC
>A>			@	25MG;250MG	N73620	001	Jun 29, 1995	Mar	DISC

CARBOPLATIN

INJECTABLE; IV (INFUSION)
CARBOPLATIN

AP	PHARMACHEMIE BV	EQ 50MG/5ML (10MG/ML)	N77679	001	Feb 25, 2009	Feb	NEWA
AP		EQ 450MG/45ML (10MG/ML)	N77679	003	Feb 25, 2009	Feb	NEWA
AP		EQ 150MG/15ML (10MG/ML)	N77679	002	Feb 25, 2009	Feb	NEWA

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

>D>	AA	SANDOZ	350MG	N81025	001	Apr 13, 1989	Mar	DISC
>A>		@	350MG	N81025	001	Apr 13, 1989	Mar	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

>A>	AP	CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	N65280	001	Mar 18, 2009	Mar	NEWA
>A>	AP		EQ 1GM BASE/VIAL	N65280	002	Mar 18, 2009	Mar	NEWA
>A>	AP		EQ 10GM BASE/VIAL	N65295	001	Mar 18, 2009	Mar	NEWA
>A>	AP		EQ 20GM BASE/VIAL	N65296	001	Mar 18, 2009	Mar	NEWA
>D>	AP	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N64033	001	Oct 31, 1993	Mar	DISC
>A>		@	EQ 1GM BASE/VIAL	N64033	001	Oct 31, 1993	Mar	DISC

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV
CEFTRIAXONE

>D>	AP	SANDOZ	EQ 2GM BASE/VIAL	N65169	004	May 09, 2005	Mar	CRLD
>A>	AP	+	EQ 2GM BASE/VIAL	N65169	004	May 09, 2005	Mar	CRLD

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE

>D>	AB	SANDOZ	100MG	N88725	001	Aug 31, 1984	Mar	DISC
>A>		@	100MG	N88725	001	Aug 31, 1984	Mar	DISC
>D>	AB		250MG	N88726	001	Aug 31, 1984	Mar	DISC
>A>		@	250MG	N88726	001	Aug 31, 1984	Mar	DISC

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

>D>	AA	SANDOZ	250MG	N89852	001	May 04, 1988	Mar	DISC
>A>		@	250MG	N89852	001	May 04, 1988	Mar	DISC
>D>	AA		500MG	N89853	001	May 04, 1988	Mar	DISC
>A>		@	500MG	N89853	001	May 04, 1988	Mar	DISC

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL
TRILIPIX

	ABBOTT LABS	EQ 45MG FENOFIBRIC ACID	N22224	001	Dec 15, 2008	Jan	CTNA
+		EQ 135MG FENOFIBRIC ACID	N22224	002	Dec 15, 2008	Jan	CTNA

CHYMOPAPAIN

INJECTABLE; INJECTION
CHYMODIACTIN

>D>	@ ABBOTT	4,000 UNITS/VIAL	N18663	002	Aug 21, 1984	Mar	CAHN

INJECTABLE; INJECTION
CHYMODIACTIN

>D>		@ ABBOTT	10,000 UNITS/VIAL	N18663	001	Nov 10, 1982	Mar	CAHN
>A>		@ CHART MEDCL	4,000 UNITS/VIAL	N18663	002	Aug 21, 1984	Mar	CAHN
>A>		@	10,000 UNITS/VIAL	N18663	001	Nov 10, 1982	Mar	CAHN

CIMETIDINE

TABLET; ORAL
CIMETIDINE

>D>	AB	SANDOZ	200MG	N74100	001	Jan 31, 1995	Mar	DISC
>A>		@	200MG	N74100	001	Jan 31, 1995	Mar	DISC
>D>	AB		300MG	N74100	002	Jan 31, 1995	Mar	DISC
>A>		@	300MG	N74100	002	Jan 31, 1995	Mar	DISC
>D>	AB		400MG	N74100	003	Jan 31, 1995	Mar	DISC
>A>		@	400MG	N74100	003	Jan 31, 1995	Mar	DISC
>D>	AB		800MG	N74100	004	Jan 31, 1995	Mar	DISC
>A>		@	800MG	N74100	004	Jan 31, 1995	Mar	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL
CIPROFLOXACIN HYDROCHLORIDE

>D>		@ MYLAN	EQ 250MG BASE	N75685	002	Jun 09, 2004	Mar	CMFD
>A>	AB		EQ 250MG BASE	N75685	002	Jun 09, 2004	Mar	CMFD
>D>		@	EQ 500MG BASE	N75685	003	Jun 09, 2004	Mar	CMFD
>A>	AB		EQ 500MG BASE	N75685	003	Jun 09, 2004	Mar	CMFD
>D>		@	EQ 750MG BASE	N75685	001	Jun 09, 2004	Mar	CMFD
>A>	AB		EQ 750MG BASE	N75685	001	Jun 09, 2004	Mar	CMFD
		@ TEVA	EQ 250MG BASE	N76136	001	Jun 09, 2004	Jan	DISC
		@	EQ 500MG BASE	N76136	002	Jun 09, 2004	Jan	DISC
		@	EQ 750MG BASE	N76136	003	Jun 09, 2004	Jan	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CITALOPRAM HYDROBROMIDE

	AB	AMNEAL PHARMS	EQ 10MG BASE	N77045	003	Apr 29, 2005	Feb	CAHN
	AB		EQ 20MG BASE	N77045	002	Apr 29, 2005	Feb	CAHN
	AB		EQ 40MG BASE	N77045	001	Apr 29, 2005	Feb	CAHN
	AB	GLENMARK GENERICS	EQ 10MG BASE	N77654	001	Feb 27, 2009	Feb	NEWA
	AB		EQ 20MG BASE	N77654	002	Feb 27, 2009	Feb	NEWA
	AB		EQ 40MG BASE	N77654	003	Feb 27, 2009	Feb	NEWA

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HYDROCHLORIDE

>D>	AB	SANDOZ	0.1MG	N70887	001	Aug 31, 1988	Mar	DISC
>A>		@	0.1MG	N70887	001	Aug 31, 1988	Mar	DISC
>D>	AB		0.2MG	N70886	001	Aug 31, 1988	Mar	DISC
>A>		@	0.2MG	N70886	001	Aug 31, 1988	Mar	DISC
>D>	AB		0.3MG	N71294	001	Aug 31, 1988	Mar	DISC
>A>		@	0.3MG	N71294	001	Aug 31, 1988	Mar	DISC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

>D>	+	SANDOZ	3.75MG	N72219	001	Aug 26, 1988	Mar	DISC
>A>		@	3.75MG	N72219	001	Aug 26, 1988	Mar	DISC

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

>D>	AB	SANDOZ	7.5MG	N72513	001	May 11, 1990	Mar	DISC
>A>		@	7.5MG	N72513	001	May 11, 1990	Mar	DISC
>D>	AB		15MG	N72514	001	May 11, 1990	Mar	DISC
>A>		@	15MG	N72514	001	May 11, 1990	Mar	DISC

CYANOCOBALAMIN

GEL, METERED; NASAL
NASCOBAL

>A>		@ PAR PHARM	0.5MG/INH	N19722	001	Nov 05, 1996	Mar	CAHN
>D>		@ QOL MEDCL	0.5MG/INH	N19722	001	Nov 05, 1996	Mar	CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
CYTOXAN

		@ BAXTER HLTHCARE	100MG/VIAL	N12142	001		Feb	CAHN
		@	200MG/VIAL	N12142	002		Feb	CAHN
		@	500MG/VIAL	N12142	003		Feb	CAHN
		@	1GM/VIAL	N12142	004	Aug 30, 1982	Feb	CAHN
		@	2GM/VIAL	N12142	005	Aug 30, 1982	Feb	CAHN

LYOPHILIZED CYTOXAN

	+	BAXTER HLTHCARE	100MG/VIAL	N12142	006	Dec 05, 1985	Feb	CAHN
	+		200MG/VIAL	N12142	007	Dec 10, 1985	Feb	CAHN
AP	+		500MG/VIAL	N12142	008	Jan 04, 1984	Feb	CAHN
AP	+		1GM/VIAL	N12142	010	Sep 24, 1985	Feb	CAHN
AP	+		2GM/VIAL	N12142	009	Dec 10, 1984	Feb	CAHN

TABLET; ORAL
CYTOXAN

		@ BAXTER HLTHCARE	25MG	N12141	002		Feb	CAHN
		@	50MG	N12141	001		Feb	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
DESOGESTREL AND ETHINYL ESTRADIOL

		@ DURAMED PHARMS BARR	0.15MG;0.03MG	N75256	001	Aug 12, 1999	Feb	DISC

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC
TOBRADEX ST

	+	ALCON	0.05%;0.3%	N50818	001	Feb 13, 2009	Feb	NEWA

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL
KAPIDEX

		TAKEDA PHARMS	30MG	N22287	001	Jan 30, 2009	Jan	NEWA
	+		60MG	N22287	002	Jan 30, 2009	Jan	NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE

>D>	AA	BARR	10MG	N40361	002	Jan 31, 2001	Mar	CRLD
>A>	AA	+	10MG	N40361	002	Jan 31, 2001	Mar	CRLD
>D>		DEXTROSTAT						
>D>	AA	+ SHIRE	5MG	N84051	001		Mar	DISC
>A>		@	5MG	N84051	001		Mar	DISC

TABLET; ORAL
DEXTROSTAT

>D>	AA	+	SHIRE	10MG	N84051	002			Mar	DISC
>A>			@	10MG	N84051	002			Mar	DISC

DIAZEPAM

TABLET; ORAL
DIAZEPAM

>D>	AB		SANDOZ	2MG	N70302	001	Dec 20, 1985		Mar	DISC
>A>			@	2MG	N70302	001	Dec 20, 1985		Mar	DISC
>D>	AB			5MG	N70303	001	Dec 20, 1985		Mar	DISC
>A>			@	5MG	N70303	001	Dec 20, 1985		Mar	DISC
>D>	AB			10MG	N70304	001	Dec 20, 1985		Mar	DISC
>A>			@	10MG	N70304	001	Dec 20, 1985		Mar	DISC

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL
DIETHYLPROPION HYDROCHLORIDE

	AA		COREPHARMA	25MG	N40828	001	Nov 05, 2008		Feb	CTEC

TENUATE

	AA	+	WATSON PHARMS	25MG	N11722	002			Feb	CTEC

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL

>D>	AB		SANDOZ	500MG	N74604	001	Jun 10, 1996		Mar	DISC
>A>			@	500MG	N74604	001	Jun 10, 1996		Mar	DISC
>D>	AB	+	TEVA	500MG	N73673	001	Jul 31, 1992		Mar	CTEC
>A>		+		500MG	N73673	001	Jul 31, 1992		Mar	CTEC

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

>D>	AA		BARR	50MG	N80738	001			Mar	CRLD
>A>		+		50MG	N80738	001			Mar	CRLD
>D>	AA		LNK	25MG	N87977	001	Jan 27, 1983		Mar	DISC
>A>			@	25MG	N87977	001	Jan 27, 1983		Mar	DISC
>D>	AA			50MG	N87978	001	Jan 27, 1983		Mar	DISC
>A>			@	50MG	N87978	001	Jan 27, 1983		Mar	DISC
>D>	AA	+	SANDOZ	25MG	N80832	001			Mar	DISC
>A>			@	25MG	N80832	001			Mar	DISC
>D>	AA	+		50MG	N80832	002			Mar	DISC
>A>			@	50MG	N80832	002			Mar	DISC
>D>	AA		VALEANT PHARM INTL	50MG	N80592	001			Mar	DISC
>A>			@	50MG	N80592	001			Mar	DISC
>D>	AA		WATSON LABS	25MG	N80728	001			Mar	DISC
>A>			@	25MG	N80728	001			Mar	DISC
>D>	AA			50MG	N80727	001			Mar	DISC
>A>			@	50MG	N80727	001			Mar	DISC

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

>D>	AB		SANDOZ	25MG	N86944	002	Apr 16, 1991		Mar	DISC
>A>			@	25MG	N86944	002	Apr 16, 1991		Mar	DISC
>D>	AB			50MG	N87562	001	Feb 25, 1992		Mar	DISC

TABLET; ORAL
DIPYRIDAMOLE

>A>		@ SANDOZ	50MG	N87562	001	Feb 25, 1992	Mar	DISC
>D>	AB		75MG	N87561	001	Feb 25, 1992	Mar	DISC
>A>		@	75MG	N87561	001	Feb 25, 1992	Mar	DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL
DEPAKOTE

	AB	+ ABBOTT	EQ 125MG VALPROIC ACID	N19680	001	Sep 12, 1989	Jan	CFTG

DIVALPROEX SODIUM

	AB	DR REDDYS LABS LTD	EQ 125MG VALPROIC ACID	N78979	001	Jan 23, 2009	Jan	NEWA
	AB	ZYDUS PHARMS USA INC	EQ 125MG VALPROIC ACID	N78919	001	Jan 27, 2009	Jan	NEWA

TABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

>A>	AB	MYLAN	EQ 125MG VALPROIC ACID	N90062	001	Mar 17, 2009	Mar	NEWA
>A>	AB		EQ 250MG VALPROIC ACID	N90062	002	Mar 17, 2009	Mar	NEWA
>A>	AB		EQ 500MG VALPROIC ACID	N90062	003	Mar 17, 2009	Mar	NEWA
	AB	ZYDUS PHARMS USA INC	EQ 125MG VALPROIC ACID	N77100	001	Mar 05, 2009	Feb	NEWA
	AB		EQ 250MG VALPROIC ACID	N77100	002	Mar 05, 2009	Feb	NEWA
	AB		EQ 500MG VALPROIC ACID	N77100	003	Mar 05, 2009	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL
DEPAKOTE ER

	AB	ABBOTT	EQ 250MG VALPROIC ACID	N21168	002	May 31, 2002	Jan	CFTG
	AB	+	EQ 500MG VALPROIC ACID	N21168	001	Aug 04, 2000	Jan	CFTG

DIVALPROEX SODIUM

	AB	ANCHEN PHARMS	EQ 250MG VALPROIC ACID	N78445	001	Feb 26, 2009	Feb	NEWA
	AB	MYLAN	EQ 250MG VALPROIC ACID	N77567	001	Jan 29, 2009	Jan	NEWA
	AB		EQ 500MG VALPROIC ACID	N77567	002	Jan 29, 2009	Jan	NEWA
	AB	WOCKHARDT	EQ 250MG VALPROIC ACID	N78705	002	Feb 10, 2009	Jan	NEWA
	AB	ZYDUS PHARMS USA INC	EQ 250MG VALPROIC ACID	N78239	001	Feb 27, 2009	Feb	NEWA

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

>A>	AT	ALCON	EQ 2% BASE	N78981	001	Apr 13, 2009	Mar	NEWA

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

		+ PAR PHARM	EQ 150MG BASE	N65055	003	Jul 15, 2005	Jan	CRLD

TABLET; ORAL
DOXYCYCLINE

>A>	AB	MUTUAL PHARM	EQ 50MG BASE	N65471	001	Apr 17, 2009	Mar	NEWA
>A>	AB		EQ 75MG BASE	N65471	002	Apr 17, 2009	Mar	NEWA
>A>	AB		EQ 100MG BASE	N65471	003	Apr 17, 2009	Mar	NEWA

DRONABINOL

CAPSULE; ORAL
DRONABINOL

>D>	AB	PAR PHARM	2.5MG	N78292	001	Jun 27, 2008	Mar	CAHN
>D>	AB		5MG	N78292	002	Jun 27, 2008	Mar	CAHN
>D>	AB		10MG	N78292	003	Jun 27, 2008	Mar	CAHN
>A>	AB	SVC PHARMA	2.5MG	N78292	001	Jun 27, 2008	Mar	CAHN
>A>	AB		5MG	N78292	002	Jun 27, 2008	Mar	CAHN
>A>	AB		10MG	N78292	003	Jun 27, 2008	Mar	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

>A>	AB		BARR	3MG;0.02MG	N78515	001	Mar 30, 2009	Mar	NEWA

YAZ

>D>		+	BAYER HLTHCARE	3MG;0.02MG	N21676	001	Mar 16, 2006	Mar	CFTG
>A>	AB	+		3MG;0.02MG	N21676	001	Mar 16, 2006	Mar	CFTG

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

>D>	AB		SANDOZ	2.5MG	N75048	001	Aug 22, 2000	Mar	DISC
>A>			@	2.5MG	N75048	001	Aug 22, 2000	Mar	DISC
>D>	AB			5MG	N75048	002	Aug 22, 2000	Mar	DISC
>A>			@	5MG	N75048	002	Aug 22, 2000	Mar	DISC
>D>	AB			10MG	N75048	003	Aug 22, 2000	Mar	DISC
>A>			@	10MG	N75048	003	Aug 22, 2000	Mar	DISC
>D>	AB			20MG	N75048	004	Aug 22, 2000	Mar	DISC
>A>			@	20MG	N75048	004	Aug 22, 2000	Mar	DISC

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

	AP	+	HOSPIRA	1.25MG/ML	N75458	001	Aug 22, 2000	Feb	CRLD

VASOTEC

			@ BIOVAIL LABS INTL	1.25MG/ML	N19309	001	Feb 09, 1988	Feb	DISC

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYZOLE

			@ ALRA	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N62758	001	Jun 15, 1988	Jan	DISC

PEDIAZOLE

			@ ROSS LABS	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N50529	001		Jan	DISC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

			@ HOSPIRA	EQ 1GM BASE/VIAL	N50182	003		Feb	DISC
	AP	+		EQ 1GM BASE/VIAL	N62638	002	Oct 31, 1986	Feb	CRLD

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL

>D>	AB		STAT-TRADE	100MG	N16320	001		Mar	CAHN
>D>			@	200MG	N16320	002		Mar	CAHN
>D>	AB			400MG	N16320	003		Mar	CAHN
>D>			@	500MG	N16320	004		Mar	CAHN
>A>	AB		STI PHARMA LLC	100MG	N16320	001		Mar	CAHN
>A>			@	200MG	N16320	002		Mar	CAHN
>A>	AB			400MG	N16320	003		Mar	CAHN
>A>			@	500MG	N16320	004		Mar	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28
ORTHO-NOVUM 10/11-28

>D>	AB	+	ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG	N18354	002	Jan 11, 1982	Mar	DISC
>A>		@		0.035MG,0.035MG;0.5MG,1MG	N18354	002	Jan 11, 1982	Mar	DISC

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21
OVRAL

>A>		@	AKRIMAX PHARMS	0.05MG;0.5MG	N16672	001		Mar	CAHN
>D>		@	WYETH PHARMS INC	0.05MG;0.5MG	N16672	001		Mar	CAHN

ETOPOSIDE

CAPSULE; ORAL
ETOPOSIDE

		+	GENPHARM	50MG	N75635	001	Sep 19, 2001	Feb	CRLD

VEPESID

		@	BRISTOL MYERS SQUIBB	50MG	N19557	001	Dec 30, 1986	Feb	DISC

>A> EVEROLIMUS

>A> TABLET; ORAL
>A> AFINITOR

>A>			NOVARTIS	5MG	N22334	001	Mar 30, 2009	Mar	NEWA
>A>		+		10MG	N22334	002	Mar 30, 2009	Mar	NEWA

FAMOTIDINE

TABLET; ORAL
FAMOTIDINE

>D>	AB		SANDOZ	20MG	N75302	001	Apr 16, 2001	Mar	DISC
>A>		@		20MG	N75302	001	Apr 16, 2001	Mar	DISC
>D>	AB			40MG	N75302	002	Apr 16, 2001	Mar	DISC
>A>		@		40MG	N75302	002	Apr 16, 2001	Mar	DISC

FEBUXOSTAT

TABLET; ORAL
ULORIC

			TAKEDA PHARMS	40MG	N21856	001	Feb 13, 2009	Feb	NEWA
		+		80MG	N21856	002	Feb 13, 2009	Feb	NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL
NALFON

		@	PEDINOL	EQ 300MG BASE	N17604	002		Feb	DISC

NALFON 200

		+	PEDINOL	EQ 200MG BASE	N17604	003		Feb	CRLD

TABLET; ORAL
FENOPROFEN CALCIUM

>D>	AB		SANDOZ	EQ 600MG BASE	N72396	001	Oct 17, 1988	Mar	DISC
>A>		@		EQ 600MG BASE	N72396	001	Oct 17, 1988	Mar	DISC

FLECAINIDE ACETATE

TABLET; ORAL
FLECAINIDE ACETATE

>D>	AB		SANDOZ	50MG	N76030	001	Oct 28, 2002	Mar	DISC
>A>		@		50MG	N76030	001	Oct 28, 2002	Mar	DISC

TABLET; ORAL
FLECAINIDE ACETATE

>D>	AB	SANDOZ	100MG	N76030	002	Oct 28, 2002	Mar	DISC
>A>		@	100MG	N76030	002	Oct 28, 2002	Mar	DISC
>D>	AB		150MG	N76030	003	Oct 28, 2002	Mar	DISC
>A>		@	150MG	N76030	003	Oct 28, 2002	Mar	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION
FLUDARABINE PHOSPHATE

	AP	ACTAVIS TOTOWA	50MG/VIAL	N78610	001	Feb 11, 2009	Feb	NEWA

FLUMAZENIL

INJECTABLE; INJECTION
FLUMAZENIL

>A>	AP	HIKMA FARMACEUTICA	0.5MG/5ML (0.1MG/ML)	N78527	001	Mar 23, 2009	Mar	NEWA
>A>	AP		1MG/10ML (0.1MG/ML)	N78527	002	Mar 23, 2009	Mar	NEWA

FLUOCINOLONE ACETONIDE

OIL; TOPICAL
DERMA-SMOOTHE/FS

	+	HILL DERMAC	0.01%	N19452	002	Nov 09, 2005	Feb	NEWA

FLUOROURACIL

SOLUTION; TOPICAL
FLUOROPLEX

		@ ELORAC	1%	N16765	001		Feb	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
FLUOXETINE HYDROCHLORIDE

>A>	AB1	ALEMBIC LTD	EQ 10MG BASE	N90223	001	Mar 19, 2009	Mar	NEWA
>A>	AB1		EQ 20MG BASE	N90223	002	Mar 19, 2009	Mar	NEWA
>A>	AB		EQ 40MG BASE	N90223	003	Mar 19, 2009	Mar	NEWA
>A>	AB1	BEIJING DOUBLE CRANE	EQ 10MG BASE	N76165	001	Feb 01, 2002	Mar	CAHN
>A>	AB1		EQ 20MG BASE	N76165	002	Feb 01, 2002	Mar	CAHN
>D>	AB1	RANBAXY	EQ 10MG BASE	N76165	001	Feb 01, 2002	Mar	CAHN
>D>	AB1		EQ 20MG BASE	N76165	002	Feb 01, 2002	Mar	CAHN

SOLUTION; ORAL
FLUOXETINE HYDROCHLORIDE

>A>	AA	AUROBINDO PHARM	EQ 20MG BASE/5ML	N79209	001	Mar 20, 2009	Mar	NEWA

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HYDROCHLORIDE

>D>	AB	SANDOZ	15MG	N71716	001	Jul 31, 1991	Mar	DISC
>A>		@	15MG	N71716	001	Jul 31, 1991	Mar	DISC
>D>	AB		30MG	N71717	001	Jul 31, 1991	Mar	DISC
>A>		@	30MG	N71717	001	Jul 31, 1991	Mar	DISC

FLURBIPROFEN

TABLET; ORAL
FLURBIPROFEN

>D>	AB	SANDOZ	50MG	N74448	001	Jul 28, 1995	Mar	DISC
>A>		@	50MG	N74448	001	Jul 28, 1995	Mar	DISC
>D>	AB		100MG	N74448	002	Jul 28, 1995	Mar	DISC

TABLET; ORAL
FLURBIPROFEN

>A>		@ SANDOZ	100MG	N74448	002	Jul 28, 1995	Mar	DISC

FLUVOXAMINE MALEATE

TABLET; ORAL
FLUVOXAMINE MALEATE

>D>	AB	IVAX PHARMS	25MG	N75898	001	Mar 12, 2001	Mar	DISC
>A>		@	25MG	N75898	001	Mar 12, 2001	Mar	DISC
>D>	AB		50MG	N75898	002	Mar 12, 2001	Mar	DISC
>A>		@	50MG	N75898	002	Mar 12, 2001	Mar	DISC
>D>	AB		100MG	N75898	003	Mar 12, 2001	Mar	DISC
>A>		@	100MG	N75898	003	Mar 12, 2001	Mar	DISC

FOMEPIZOLE

INJECTABLE; INJECTION
FOMEPIZOLE

>A>	AP	GENERAMEDIX	1.5GM/1.5ML (1GM/ML)	N79033	001	Apr 07, 2009	Mar	NEWA

FOSINOPRIL SODIUM

TABLET; ORAL
FOSINOPRIL SODIUM

>D>	AB	SANDOZ	10MG	N76188	001	Oct 08, 2004	Mar	DISC
>A>		@	10MG	N76188	001	Oct 08, 2004	Mar	DISC
>D>	AB		20MG	N76188	002	Oct 08, 2004	Mar	DISC
>A>		@	20MG	N76188	002	Oct 08, 2004	Mar	DISC
>D>	AB		40MG	N76188	003	Oct 08, 2004	Mar	DISC
>A>		@	40MG	N76188	003	Oct 08, 2004	Mar	DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL
MONOPRIL-HCT

		@ BRISTOL MYERS SQUIBB	10MG;12.5MG	N20286	002	Nov 30, 1994	Feb	DISC
		@	20MG;12.5MG	N20286	001	Nov 30, 1994	Feb	DISC

GALANTAMINE HYDROBROMIDE

SOLUTION; ORAL
GALANTAMINE HYDROBROMIDE

	AA	ROXANE	4MG/ML	N78185	001	Jan 30, 2009	Jan	NEWA

RAZADYNE

	AA	+ ORTHO MCNEIL JANSSEN	4MG/ML	N21224	001	Jun 22, 2001	Jan	CFTG

TABLET; ORAL
GALANTAMINE HYDROBROMIDE

	AB	PAR PHARM	EQ 4MG BASE	N77604	001	Feb 06, 2009	Jan	NEWA
	AB		EQ 8MG BASE	N77604	002	Feb 06, 2009	Jan	NEWA
	AB		EQ 12MG BASE	N77604	003	Feb 06, 2009	Jan	NEWA
	AB	ROXANE	EQ 4MG BASE	N77608	001	Feb 11, 2009	Jan	NEWA
	AB		EQ 8MG BASE	N77608	002	Feb 11, 2009	Jan	NEWA
	AB		EQ 12MG BASE	N77608	003	Feb 11, 2009	Jan	NEWA

GLYBURIDE

TABLET; ORAL
GLYBURIDE

>D>	AB	TEVA	5MG	N74388	003	Aug 29, 1995	Mar	CRLD
>A>	AB	+	5MG	N74388	003	Aug 29, 1995	Mar	CRLD

TABLET; ORAL
MICRONASE

>D>	AB		PHARMACIA AND UPJOHN	1.25MG	N17498	001	May 01, 1984	Mar	DISC
>A>		@		1.25MG	N17498	001	May 01, 1984	Mar	DISC
>D>	AB			2.5MG	N17498	002	May 01, 1984	Mar	DISC
>A>		@		2.5MG	N17498	002	May 01, 1984	Mar	DISC
>D>	AB	+		5MG	N17498	003	May 01, 1984	Mar	DISC
>A>		@		5MG	N17498	003	May 01, 1984	Mar	DISC

GLYCOPYRROLATE

TABLET; ORAL
GLYCOPYRROLATE

	AA		WEST WARD	1MG	N40836	001	Mar 05, 2009	Feb	NEWA
	AA			2MG	N40836	002	Mar 05, 2009	Feb	NEWA

GRANISETRON HYDROCHLORIDE

TABLET; ORAL
GRANISETRON HYDROCHLORIDE

	AB		DR REDDYS LABS LTD	EQ 1MG BASE	N78846	001	Feb 27, 2009	Feb	NEWA

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS
VANTAS

>A>		+	ENDO PHARMS	50MG	N21732	001	Oct 12, 2004	Mar	CAHN
>D>		+	INDEVUS	50MG	N21732	001	Oct 12, 2004	Mar	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL
HYCODAN

		@	ENDO PHARMS	1.5MG/5ML;5MG/5ML	N05213	002	Jul 26, 1988	Feb	DISC

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

	AA	+	HI TECH PHARMA	1.5MG/5ML;5MG/5ML	N40613	001	Feb 08, 2008	Feb	CRLD

TABLET; ORAL
HYCODAN

		@	ENDO PHARMS	1.5MG;5MG	N05213	001	Jul 26, 1988	Feb	DISC

TUSSIGON

	AA	+	KING PHARMS	1.5MG;5MG	N88508	001	Jul 30, 1985	Feb	CRLD

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HYDROCHLORIDE

>A>	AP		AKORN	20MG/ML	N40730	001	Apr 21, 2009	Mar	NEWA

TABLET; ORAL
HYDRALAZINE HYDROCHLORIDE

>D>	AA		SANDOZ	10MG	N83241	001		Mar	DISC
>A>		@		10MG	N83241	001		Mar	DISC
>D>	AA			25MG	N83560	001		Mar	DISC
>A>		@		25MG	N83560	001		Mar	DISC
>D>	AA			50MG	N83561	001		Mar	DISC
>A>		@		50MG	N83561	001		Mar	DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDROCHLOROTHIAZIDE

>A>	AB		IPCA LABS LTD	12.5MG	N79237	001	Apr 02, 2009	Mar	NEWA

>D>		SOLUTION; ORAL							
>D>		HYDROCHLOROTHIAZIDE							
>D>	+	ROXANE	50MG/5ML	N88587	001	Jul 02, 1984	Mar	DISC	
>A>		@	50MG/5ML	N88587	001	Jul 02, 1984	Mar	DISC	
		TABLET; ORAL							
		HYDROCHLOROTHIAZIDE							
>D>	AB	SANDOZ	25MG	N87565	001	Mar 09, 1982	Mar	DISC	
>A>		@	25MG	N87565	001	Mar 09, 1982	Mar	DISC	
>D>	AB		50MG	N84912	001		Mar	DISC	
>A>		@	50MG	N84912	001		Mar	DISC	
		HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE							
		TABLET; ORAL							
		PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
>D>	AB	SANDOZ	25MG;40MG	N71060	001	Aug 26, 1987	Mar	DISC	
>A>		@	25MG;40MG	N71060	001	Aug 26, 1987	Mar	DISC	
>D>	AB		25MG;80MG	N71061	001	Aug 26, 1987	Mar	DISC	
>A>		@	25MG;80MG	N71061	001	Aug 26, 1987	Mar	DISC	
		HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE							
		TABLET; ORAL							
		QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
	AB	RANBAXY	12.5MG;EQ 10MG BASE	N78211	001	Mar 04, 2009	Feb	NEWA	
	AB		12.5MG;EQ 20MG BASE	N78211	002	Mar 04, 2009	Feb	NEWA	
	AB		25MG;EQ 20MG BASE	N78211	003	Mar 04, 2009	Feb	NEWA	
		HYDROCHLOROTHIAZIDE; SPIRONOLACTONE							
		TABLET; ORAL							
		SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE							
>D>	AB	SANDOZ	25MG;25MG	N86881	001		Mar	DISC	
>A>		@	25MG;25MG	N86881	001		Mar	DISC	
		HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE							
		SUSPENSION; OPHTHALMIC							
		TERRA-CORTRIL							
		@ PFIZER	1.5%;EQ 5MG BASE/ML	N61016	001		Feb	DISC	
		HYDROXYUREA							
		CAPSULE; ORAL							
		HYDROXYUREA							
	AB	BARR	500MG	N75143	001	Oct 16, 1998	Feb	CMFD	
		HYDROXYZINE HYDROCHLORIDE							
		TABLET; ORAL							
		HYDROXYZINE HYDROCHLORIDE							
>D>	AB	SANDOZ	10MG	N87869	001	Dec 20, 1982	Mar	DISC	
>A>		@	10MG	N87869	001	Dec 20, 1982	Mar	DISC	
>D>	AB		25MG	N87870	001	Dec 20, 1982	Mar	DISC	
>A>		@	25MG	N87870	001	Dec 20, 1982	Mar	DISC	
>D>	AB		50MG	N87871	001	Dec 20, 1982	Mar	DISC	
>A>		@	50MG	N87871	001	Dec 20, 1982	Mar	DISC	
		HYDROXYZINE PAMOATE							
		CAPSULE; ORAL							
		HYDROXYZINE PAMOATE							
>D>	AB	SANDOZ	EQ 25MG HCL	N81127	001	Jun 28, 1991	Mar	DISC	

		CAPSULE; ORAL							
		HYDROXYZINE PAMOATE							
>A>		@ SANDOZ	EQ 25MG HCL	N81127	001	Jun 28, 1991	Mar	DISC	
		IBUPROFEN							
		TABLET; ORAL							
		IBUPROFEN							
	AB	+ DR REDDYS LA	800MG	N75682	003	Nov 14, 2001	Feb	CRLD	
>D>	AB	SANDOZ	300MG	N70734	001	Jun 12, 1986	Mar	DISC	
>A>		@	300MG	N70734	001	Jun 12, 1986	Mar	DISC	
>D>	AB		400MG	N70735	001	Jun 12, 1986	Mar	DISC	
>A>		@	400MG	N70735	001	Jun 12, 1986	Mar	DISC	
>D>	AB		600MG	N70736	001	Jun 12, 1986	Mar	DISC	
>A>		@	600MG	N70736	001	Jun 12, 1986	Mar	DISC	
>D>	AB		800MG	N72169	001	Dec 11, 1987	Mar	DISC	
>A>		@	800MG	N72169	001	Dec 11, 1987	Mar	DISC	
	AB	SHASUN USA	400MG	N78329	001	Feb 05, 2009	Jan	NEWA	
	AB		600MG	N78329	002	Feb 05, 2009	Jan	NEWA	
	AB		800MG	N78329	003	Feb 05, 2009	Jan	NEWA	
		MOTRIN							
		@ MCNEIL CONSUMER	400MG	N17463	002		Feb	DISC	
		@	600MG	N17463	004		Feb	DISC	
		@	800MG	N17463	005	May 22, 1985	Feb	DISC	
		IFOSFAMIDE							
		INJECTABLE; INJECTION							
		IFEX							
		@ BAXTER HLTHCARE	1GM/VIAL	N19763	001	Dec 30, 1988	Feb	CAHN	
		@	3GM/VIAL	N19763	002	Dec 30, 1988	Feb	CAHN	
		IFOSFAMIDE; MESNA							
		INJECTABLE; INJECTION							
		IFEX/MESNEX KIT							
		+ BAXTER HLTHCARE	1GM/VIAL;100MG/ML	N19763	003	Oct 10, 1992	Feb	CAHN	
		+	3GM/VIAL;100MG/ML	N19763	004	Oct 10, 1992	Feb	CAHN	
		INDOMETHACIN							
		CAPSULE, EXTENDED RELEASE; ORAL							
		INDOCIN SR							
	AB	+ SANDOZ	75MG	N74464	001	May 28, 1998	Feb	CTEC	
		INDOMETHACIN							
	AB	AVANTHI INC	75MG	N79175	001	Mar 06, 2009	Feb	NEWA	
		SUSPENSION; ORAL							
		INDOCIN							
>A>		+ IROKO PHARMS	25MG/5ML	N18332	001	Oct 10, 1985	Mar	CAHN	
>D>		+ MERCK	25MG/5ML	N18332	001	Oct 10, 1985	Mar	CAHN	
		INSULIN GLULISINE RECOMBINANT							
		INJECTABLE; SUBCUTANEOUS							
		APIDRA SOLOSTAR							
		SANOFI AVENTIS US	300 UNITS/3ML	N21629	003	Feb 24, 2009	Feb	NEWA	
		IRINOTECAN HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		IRINOTECAN HYDROCHLORIDE							
>A>	AP	PHARMAFORCE	40MG/2ML (20MG/ML)	N90016	001	Jan 28, 2009	Mar	NEWA	

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

	AP	PHARMAFORCE	40MG/2ML(20MG/ML)	N90016	001	Jan 28, 2009	Jan	NEWA
>A>	AP		100MG/5ML (20MG/ML)	N90016	002	Jan 28, 2009	Mar	NEWA
	AP		100MG/5ML(20MG/ML)	N90016	002	Jan 28, 2009	Jan	NEWA

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL
ISOSORBIDE DINITRATE

>D>	AB	SANDOZ	2.5MG	N86225	001	Feb 19, 1988	Mar	DISC
>A>		@	2.5MG	N86225	001	Feb 19, 1988	Mar	DISC
>D>	AB		5MG	N86222	001	Feb 19, 1988	Mar	DISC
>A>		@	5MG	N86222	001	Feb 19, 1988	Mar	DISC

KETOCONAZOLE

GEL; TOPICAL
XOLEGEL

	+	STIEFEL LABS INC	2%	N21946	001	Jul 28, 2006	Jan	CAHN

KETOPROFEN

CAPSULE; ORAL
KETOPROFEN

>D>	AB	SANDOZ	50MG	N74024	001	Dec 29, 1995	Mar	DISC
>A>		@	50MG	N74024	001	Dec 29, 1995	Mar	DISC
>D>	AB		75MG	N74024	002	Dec 29, 1995	Mar	DISC
>A>		@	75MG	N74024	002	Dec 29, 1995	Mar	DISC

LAMOTRIGINE

TABLET; ORAL
LAMOTRIGINE

	AB	APOTEX INC	25MG	N78625	001	Jan 27, 2009	Jan	NEWA
	AB		100MG	N78625	002	Jan 27, 2009	Jan	NEWA
	AB		150MG	N78625	003	Jan 27, 2009	Jan	NEWA
	AB		200MG	N78625	004	Jan 27, 2009	Jan	NEWA
	AB	AUROBINDO PHARMA	25MG	N78956	001	Jan 27, 2009	Jan	NEWA
	AB		100MG	N78956	002	Jan 27, 2009	Jan	NEWA
	AB		150MG	N78956	003	Jan 27, 2009	Jan	NEWA
	AB		200MG	N78956	004	Jan 27, 2009	Jan	NEWA
	AB	CADISTA PHARMS	25MG	N79132	001	Jan 27, 2009	Jan	NEWA
	AB		100MG	N79132	002	Jan 27, 2009	Jan	NEWA
	AB		150MG	N79132	003	Jan 27, 2009	Jan	NEWA
	AB		200MG	N79132	004	Jan 27, 2009	Jan	NEWA
	AB	DR REDDYS LABS LTD	25MG	N76708	001	Jan 27, 2009	Jan	NEWA
	AB		100MG	N76708	002	Jan 27, 2009	Jan	NEWA
	AB		150MG	N76708	003	Jan 27, 2009	Jan	NEWA
	AB		200MG	N76708	004	Jan 27, 2009	Jan	NEWA
	AB	GENPHARM ULC	25MG	N77428	001	Jan 27, 2009	Jan	NEWA
	AB		100MG	N77428	002	Jan 27, 2009	Jan	NEWA
	AB		150MG	N77428	003	Jan 27, 2009	Jan	NEWA
	AB		200MG	N77428	004	Jan 27, 2009	Jan	NEWA
	AB	MATRIX LABS LTD	25MG	N78443	001	Feb 11, 2009	Jan	NEWA
	AB		100MG	N78443	002	Feb 11, 2009	Jan	NEWA
	AB		150MG	N78443	003	Feb 11, 2009	Jan	NEWA
	AB		200MG	N78443	004	Feb 11, 2009	Jan	NEWA
	AB	MYLAN	25MG	N77420	001	Jan 27, 2009	Jan	NEWA
	AB		100MG	N77420	002	Jan 27, 2009	Jan	NEWA

TABLET; ORAL

LAMOTRIGINE

AB	MYLAN	150MG	N77420	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77420	004	Jan 27, 2009	Jan	NEWA
AB	ROXANE	25MG	N77392	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77392	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77392	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77392	004	Jan 27, 2009	Jan	NEWA
AB	SANDOZ	25MG	N78645	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78645	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78645	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78645	004	Jan 27, 2009	Jan	NEWA
AB	TARO PHARM INDS	25MG	N78525	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78525	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78525	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78525	004	Jan 27, 2009	Jan	NEWA
AB	TORRENT PHARMS	25MG	N78947	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78947	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78947	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78947	004	Jan 27, 2009	Jan	NEWA
AB	UPSHER SMITH	25MG	N78310	001	Feb 04, 2009	Jan	NEWA
AB		100MG	N78310	002	Feb 04, 2009	Jan	NEWA
AB		150MG	N78310	003	Feb 04, 2009	Jan	NEWA
AB		200MG	N78310	004	Feb 04, 2009	Jan	NEWA
AB	WOCKHARDT	25MG	N78982	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78982	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78982	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78982	004	Jan 27, 2009	Jan	NEWA
AB	ZYDUS PHARMS USA	25MG	N77633	001	Jan 27, 2009	Jan	NEWA
		50MG	N77633	002	Jan 27, 2009	Jan	NEWA
AB		100MG	N77633	003	Jan 27, 2009	Jan	NEWA
AB		150MG	N77633	004	Jan 27, 2009	Jan	NEWA
AB		200MG	N77633	005	Jan 27, 2009	Jan	NEWA
		250MG	N77633	006	Jan 27, 2009	Jan	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	GLENMARK GENERICS	5MG	N79099	001	Feb 19, 2009	Feb	NEWA
AB		25MG	N79099	002	Feb 19, 2009	Feb	NEWA
AB	TARO	5MG	N79204	001	Feb 04, 2009	Jan	NEWA
AB		25MG	N79204	002	Feb 04, 2009	Jan	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

AP	SUN PHARMA GLOBAL	1MG/0.2ML	N78885	001	Mar 09, 2009	Feb	NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

>A> AN	DEY	EQ 0.25% BASE	N78309	001	Mar 20, 2009	Mar	NEWA

XOPENEX

>D> +	SEPRACOR	EQ 0.25% BASE	N20837	004	Jul 18, 2003	Mar	CFTG
>A> AN +		EQ 0.25% BASE	N20837	004	Jul 18, 2003	Mar	CFTG

LEVETIRACETAM

SOLUTION; ORAL
LEVETIRACETAM

>A>	AA	SILARX	100MG/ML	N90263	001	Apr 03, 2009	Mar	NEWA
	AA	TARO	100MG/ML	N78774	001	Feb 10, 2009	Jan	NEWA

TABLET; ORAL
LEVETIRACETAM

>A>	AB	APOTEX INC	250MG	N78869	001	Mar 13, 2009	Mar	NEWA
>A>	AB		500MG	N78869	002	Mar 13, 2009	Mar	NEWA
>A>	AB		750MG	N78869	003	Mar 13, 2009	Mar	NEWA
>A>	AB		1GM	N78869	004	Mar 13, 2009	Mar	NEWA
>A>	AB	CIPLA LTD	250MG	N77319	001	Mar 20, 2009	Mar	NEWA
>A>	AB		500MG	N77319	002	Mar 20, 2009	Mar	NEWA
>A>	AB		750MG	N77319	003	Mar 20, 2009	Mar	NEWA
	AB	GENPHARM ULC	250MG	N78731	001	Feb 10, 2009	Jan	NEWA
	AB		500MG	N78731	002	Feb 10, 2009	Jan	NEWA
	AB		750MG	N78731	003	Feb 10, 2009	Jan	NEWA
	AB		1GM	N78731	004	Feb 10, 2009	Jan	NEWA
	AB	SOLCO HLTHCARE	250MG	N78106	001	Feb 10, 2009	Jan	NEWA
	AB		500MG	N78106	002	Feb 10, 2009	Jan	NEWA
	AB		750MG	N78106	003	Feb 10, 2009	Jan	NEWA
	AB		1GM	N78106	004	Feb 10, 2009	Jan	NEWA
	AB	WATSON LABS FLORIDA	250MG	N77408	001	Mar 02, 2009	Feb	NEWA
	AB		500MG	N77408	002	Mar 02, 2009	Feb	NEWA
	AB		750MG	N77408	003	Mar 02, 2009	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL
KEPPRA XR

		UCB INC	500MG	N22285	001	Sep 12, 2008	Feb	CRLD
	+		750MG	N22285	002	Feb 12, 2009	Feb	NEWA

LINDANE

SHAMPOO; TOPICAL
LINDANE

	AT	+ OLTA PHARMS	1%	N87266	001		Jan	CAHN

LIOTHYRONINE SODIUM

TABLET; ORAL
CYTOMEL

>D>		KING PHARMS	EQ 0.005MG BASE	N10379	001		Mar	CFTG
>A>	AB		EQ 0.005MG BASE	N10379	001		Mar	CFTG
>D>			EQ 0.025MG BASE	N10379	002		Mar	CTEC
>A>	AB		EQ 0.025MG BASE	N10379	002		Mar	CTEC
>D>	+		EQ 0.05MG BASE	N10379	003		Mar	CTEC
>A>	AB +		EQ 0.05MG BASE	N10379	003		Mar	CTEC

>A> LIOTHYRONINE SODIUM

>A>	AB	COASTAL PHARMS	EQ 0.005MG BASE	N90097	001	Mar 20, 2009	Mar	NEWA
>A>	AB		EQ 0.025MG BASE	N90097	002	Mar 20, 2009	Mar	NEWA
>A>	AB		EQ 0.05MG BASE	N90097	003	Mar 20, 2009	Mar	NEWA

LITHIUM CARBONATE

CAPSULE; ORAL
LITHIUM CARBONATE

	AB	GLENMARK GENERICS	150MG	N79139	001	Feb 03, 2009	Jan	NEWA
	AB		300MG	N79139	002	Feb 03, 2009	Jan	NEWA
	AB		600MG	N79139	003	Feb 03, 2009	Jan	NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
LOPERAMIDE HYDROCHLORIDE

>D>	AB		SANDOZ	2MG	N72993	001	Aug 28, 1992	Mar	DISC
>A>			@	2MG	N72993	001	Aug 28, 1992	Mar	DISC

LORAZEPAM

>D>			SOLUTION; ORAL						
>D>			LORAZEPAM						
>D>			ROXANE	0.5MG/5ML	N74648	001	Mar 18, 1997	Mar	DISC
>A>			@	0.5MG/5ML	N74648	001	Mar 18, 1997	Mar	DISC

MALATHION

LOTION; TOPICAL
MALATHION

	AT		SYNERX PHARMA	0.5%	N78743	001	Mar 06, 2009	Feb	NEWA

OVIDE

	AT	+	TARO PHARMS NORTH	0.5%	N18613	001	Aug 02, 1982	Feb	CFTG

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
ANTIVERT

	AA	+	PFIZER	12.5MG	N10721	006		Jan	CAHN
	AA	+		25MG	N10721	004		Jan	CAHN
	AA	+		50MG	N10721	001	Jan 20, 1982	Jan	CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL
MECLOFENAMATE SODIUM

>D>	AB		SANDOZ	EQ 50MG BASE	N72262	001	Nov 29, 1988	Mar	DISC
>A>			@	EQ 50MG BASE	N72262	001	Nov 29, 1988	Mar	DISC
>D>	AB			EQ 100MG BASE	N72263	001	Nov 29, 1988	Mar	DISC
>A>			@	EQ 100MG BASE	N72263	001	Nov 29, 1988	Mar	DISC

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

	AA		ALEMBIC LTD	200MG	N90122	001	Feb 18, 2009	Feb	NEWA
	AA			400MG	N90122	002	Feb 18, 2009	Feb	NEWA

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL
SOLAGE

		+	STIEFEL LABS INC	2%;0.01%	N20922	001	Dec 10, 1999	Jan	CAHN

METAPROTERENOL SULFATE

SOLUTION; INHALATION
ALUPENT

			@ BOEHRINGER INGELHEIM	0.4%	N18761	002	Oct 10, 1986	Feb	DISC
			@	0.6%	N18761	001	Jun 30, 1983	Feb	DISC

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE

	AB		ALVOGEN	500MG	N76033	001	Jan 24, 2002	Jan	CAHN

		TABLET; ORAL							
		METFORMIN HYDROCHLORIDE							
	AB	ALVOGEN	850MG	N76033	002	Jan 24, 2002	Jan	CAHN	
	AB		1GM	N76033	003	Jan 24, 2002	Jan	CAHN	
		TABLET, EXTENDED RELEASE; ORAL							
		METFORMIN HYDROCHLORIDE							
>D>	AB	SANDOZ	500MG	N76223	001	Dec 14, 2004	Mar	DISC	
>A>		@	500MG	N76223	001	Dec 14, 2004	Mar	DISC	

METHOCARBAMOL

		TABLET; ORAL							
		METHOCARBAMOL							
		@ SOLCO HLTHCARE	500MG	N86989	001		Jan	CAHN	
		@	750MG	N86988	001		Jan	CAHN	

METHOTREXATE SODIUM

		INJECTABLE; INJECTION							
		METHOTREXATE SODIUM PRESERVATIVE FREE							
>A>	AP	EBEWE PARENTA	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	N90039	001	Mar 31, 2009	Mar	NEWA	
>A>	AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	N90039	002	Mar 31, 2009	Mar	NEWA	
>A>	AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N90029	001	Mar 31, 2009	Mar	NEWA	

METHYCLOTHIAZIDE

		TABLET; ORAL							
		ENDURON							
>D>	AB	ABBOTT	2.5MG	N12524	001		Mar	CTEC	
>A>			2.5MG	N12524	001		Mar	CTEC	
		METHYCLOTHIAZIDE							
>D>	AB	SANDOZ	2.5MG	N89835	001	Aug 18, 1988	Mar	DISC	
>A>		@	2.5MG	N89835	001	Aug 18, 1988	Mar	DISC	
>D>	AB		5MG	N89837	001	Aug 18, 1988	Mar	DISC	
>A>		@	5MG	N89837	001	Aug 18, 1988	Mar	DISC	

METHYLDOPA

		TABLET; ORAL							
		METHYLDOPA							
>D>	AB	SANDOZ	125MG	N71700	001	Mar 02, 1988	Mar	DISC	
>A>		@	125MG	N71700	001	Mar 02, 1988	Mar	DISC	
>D>	AB		250MG	N18934	001	Jun 29, 1984	Mar	DISC	
>A>		@	250MG	N18934	001	Jun 29, 1984	Mar	DISC	
>D>	AB		500MG	N18934	002	Jun 29, 1984	Mar	DISC	
>A>		@	500MG	N18934	002	Jun 29, 1984	Mar	DISC	

METHYLPREDNISOLONE ACETATE

		INJECTABLE; INJECTION							
		METHYLPREDNISOLONE ACETATE							
	AB	SANDOZ	40MG/ML	N40719	001	Jan 29, 2009	Jan	NEWA	
	AB		40MG/ML	N40794	001	Mar 05, 2009	Feb	NEWA	
	AB		80MG/ML	N40719	002	Jan 29, 2009	Jan	NEWA	
	AB		80MG/ML	N40794	002	Mar 05, 2009	Feb	NEWA	

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE

>D>		@ VISTAPHARM	EQ 5MG BASE/5ML	N75051	001	Jan 26, 2001	Mar	CMFD

METOCLOPRAMIDE HYDROCHLORIDE

>A>	AA	VISTAPHARM	EQ 5MG BASE/5ML	N75051	001	Jan 26, 2001	Mar	CMFD

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>D>	AB	SANDOZ	EQ 5MG BASE	N74478	001	Oct 05, 1995	Mar	DISC
>A>		@	EQ 5MG BASE	N74478	001	Oct 05, 1995	Mar	DISC
>D>	AB		EQ 10MG BASE	N72215	001	Jan 30, 1990	Mar	DISC
>A>		@	EQ 10MG BASE	N72215	001	Jan 30, 1990	Mar	DISC

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

		@ SOLCO HLTHCARE	50MG	N74453	001	Apr 27, 1995	Jan	CAHN
		@	100MG	N74453	002	Apr 27, 1995	Jan	CAHN

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

>A>	AB	ALEMBIC LTD	250MG	N79067	001	Mar 13, 2009	Mar	NEWA
>A>	AB		500MG	N79067	002	Mar 13, 2009	Mar	NEWA
>D>	AB	SANDOZ	250MG	N18740	001	Oct 22, 1982	Mar	DISC
>A>		@	250MG	N18740	001	Oct 22, 1982	Mar	DISC
>D>	AB		500MG	N18740	002	Oct 22, 1982	Mar	DISC
>A>		@	500MG	N18740	002	Oct 22, 1982	Mar	DISC

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

>D>	AB	SANDOZ	150MG	N74450	001	May 16, 1996	Mar	DISC
>A>		@	150MG	N74450	001	May 16, 1996	Mar	DISC
>D>	AB		200MG	N74450	002	May 16, 1996	Mar	DISC
>A>		@	200MG	N74450	002	May 16, 1996	Mar	DISC
>D>	AB		250MG	N74450	003	May 16, 1996	Mar	DISC
>A>		@	250MG	N74450	003	May 16, 1996	Mar	DISC

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

	+	STIEFEL LABS INC	0.25%;81.35%;15%	N21026	001	Feb 16, 2006	Jan	CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

		CYPRESS BIOSCIENCE	12.5MG	N22256	001	Jan 14, 2009	Jan	NEWA
			25MG	N22256	002	Jan 14, 2009	Jan	NEWA
			50MG	N22256	003	Jan 14, 2009	Jan	NEWA
	+		100MG	N22256	004	Jan 14, 2009	Jan	NEWA

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

>A>	AB		BARR	EQ 45MG BASE	N65485	001	Mar 17, 2009	Mar	NEWA
>A>	AB			EQ 90MG BASE	N65485	002	Mar 17, 2009	Mar	NEWA
>A>	AB			EQ 135MG BASE	N65485	003	Mar 17, 2009	Mar	NEWA
	AB		IMPAX LABS INC	EQ 45MG BASE	N90024	001	Feb 03, 2009	Jan	NEWA
	AB			EQ 90MG BASE	N90024	002	Feb 03, 2009	Jan	NEWA
	AB			EQ 135MG BASE	N90024	003	Feb 03, 2009	Jan	NEWA

SOLODYN

	AB		MEDICIS	EQ 45MG BASE	N50808	001	May 08, 2006	Jan	CFTG
	AB			EQ 90MG BASE	N50808	002	May 08, 2006	Jan	CFTG
	AB	+		EQ 135MG BASE	N50808	003	May 08, 2006	Jan	CFTG

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

>A>	AP		GENERAMEDIX	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N78980	001	Apr 13, 2009	Mar	NEWA
>A>	AP			EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	N78980	002	Apr 13, 2009	Mar	NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

		+	ACTAVIS ELIZABETH	10MG	N20616	008	Apr 20, 2007	Feb	CRLD
		+		80MG	N20616	006	Oct 27, 2006	Feb	CRLD

NABUMETONE

TABLET; ORAL

NABUMETONE

	AB		ACTAVIS ELIZABETH	500MG	N79093	001	Feb 27, 2009	Feb	NEWA
	AB			750MG	N79093	002	Feb 27, 2009	Feb	NEWA
>D>	AB		SANDOZ	500MG	N75590	001	Feb 25, 2002	Mar	DISC
>A>		@		500MG	N75590	001	Feb 25, 2002	Mar	DISC
>D>	AB			750MG	N75590	002	Feb 25, 2002	Mar	DISC
>A>		@		750MG	N75590	002	Feb 25, 2002	Mar	DISC

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

>D>	AB	+	STAT TRADE	EQ 375MG BASE	N20353	001	Jan 05, 1996	Mar	CTEC
>A>		+		EQ 375MG BASE	N20353	001	Jan 05, 1996	Mar	CTEC
>D>	AB	+		EQ 500MG BASE	N20353	002	Jan 05, 1996	Mar	CTEC
>A>		+		EQ 500MG BASE	N20353	002	Jan 05, 1996	Mar	CTEC

>D>

NAPROXEN SODIUM

>D>	AB		WATSON LABS FLORIDA	EQ 375MG BASE	N75416	002	Apr 23, 2003	Mar	DISC
>A>		@		EQ 375MG BASE	N75416	002	Apr 23, 2003	Mar	DISC
>D>	AB			EQ 500MG BASE	N75416	001	Aug 27, 2002	Mar	DISC
>A>		@		EQ 500MG BASE	N75416	001	Aug 27, 2002	Mar	DISC

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

>D>	AB		BARR	30MG	N77811	001	May 02, 2007	Mar	CRLD

CAPSULE; ORAL
NIMODIPINE

>A>	AB	+	BARR	30MG	N77811	001	May 02, 2007	Mar	CRLD
			NIMOTOP						
			@ BAYER PHARMS	30MG	N18869	001	Dec 28, 1988	Feb	DISC

NITISINONE

CAPSULE; ORAL
ORFADIN

>A>			RARE DIS	2MG	N21232	001	Jan 18, 2002	Mar	CAHN
>A>				5MG	N21232	002	Jan 18, 2002	Mar	CAHN
>A>		+		10MG	N21232	003	Jan 18, 2002	Mar	CAHN
>D>			SWEDISH ORPHAN	2MG	N21232	001	Jan 18, 2002	Mar	CAHN
>D>				5MG	N21232	002	Jan 18, 2002	Mar	CAHN
>D>		+		10MG	N21232	003	Jan 18, 2002	Mar	CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTOIN

>D>	AB		SANDOZ	25MG	N74336	001	Jan 25, 1995	Mar	DISC
>A>			@	25MG	N74336	001	Jan 25, 1995	Mar	DISC
>D>	AB			50MG	N74336	002	Jan 25, 1995	Mar	DISC
>A>			@	50MG	N74336	002	Jan 25, 1995	Mar	DISC
>D>	AB			100MG	N74336	003	Jan 25, 1995	Mar	DISC
>A>			@	100MG	N74336	003	Jan 25, 1995	Mar	DISC

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
OFLOXACIN

	AT		FDC LTD	0.3%	N78559	001	Feb 25, 2009	Feb	NEWA

TABLET; ORAL
FLOXIN

>D>										
>D>	AB		ORTHO MCNEIL JANSSEN	200MG	N19735	001	Dec 28, 1990	Mar	DISC
>A>			@	200MG	N19735	001	Dec 28, 1990	Mar	DISC
>D>	AB			300MG	N19735	002	Dec 28, 1990	Mar	DISC
>A>			@	300MG	N19735	002	Dec 28, 1990	Mar	DISC
>D>	AB			400MG	N19735	003	Dec 28, 1990	Mar	DISC
>A>			@	400MG	N19735	003	Dec 28, 1990	Mar	DISC

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE

>A>	AB		DR REDDYS LABS	40MG	N78490	001	Apr 17, 2009	Mar	NEWA
>A>	AB		DR REDDYS LABS LTD	10MG	N78693	001	Mar 16, 2009	Mar	NEWA
>A>	AB			20MG	N78693	002	Mar 16, 2009	Mar	NEWA
	AB		KREMERS URBAN DEV	40MG	N75410	003	Jan 23, 2009	Jan	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

>A>	AP		BEDFORD LABS	EQ 0.64MG BASE/ML	N78291	001	Apr 13, 2009	Mar	NEWA

OXAPROZIN

TABLET; ORAL
OXAPROZIN

>D>	AB		SANDOZ	600MG	N75850	001	Apr 27, 2001	Mar	DISC

TABLET; ORAL
OXAPROZIN
>A> @ SANDOZ 600MG N75850 001 Apr 27, 2001 Mar DISC

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL
>A> GELNIQUE
>A> + WATSON LABS 10%(100MG/PACKET) N22204 001 Jan 27, 2009 Mar CTNA
>D> OXYBUTYNIN CHLORIDE
>D> + WATSON LABS 10%(100MG/PACKET) N22204 001 Jan 27, 2009 Mar CTNA
+ 10%(100MG/PACKET) N22204 001 Jan 27, 2009 Jan NEWA

TABLET, EXTENDED RELEASE; ORAL
OXYBUTYIN CHLORIDE
AB OSMOTICA PHARM 5MG N78503 001 Feb 04, 2009 Jan NEWA
AB 10MG N78503 002 Feb 04, 2009 Jan NEWA
AB 15MG N78503 003 Feb 04, 2009 Jan NEWA

OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE HYDROCHLORIDE
>A> AB SUN PHARM INDS INC 5MG N90659 001 Apr 10, 2009 Mar NEWA
>A> AB 15MG N90659 002 Apr 10, 2009 Mar NEWA
>A> AB 30MG N90659 003 Apr 10, 2009 Mar NEWA
>A> AB VINTAGE PHARMS 5MG N77712 003 Mar 02, 2009 Mar NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
PAMIDRONATE DISODIUM
AP GENERAMEDIX 30MG/VIAL N78300 001 Mar 10, 2009 Feb NEWA
AP 90MG/VIAL N78300 002 Mar 10, 2009 Feb NEWA

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM
>A> AB KUDCO IRELAND EQ 20MG BASE N78281 001 Mar 17, 2009 Mar NEWA
>A> AB EQ 40MG BASE N78281 002 Mar 17, 2009 Mar NEWA

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL
>D> VEETIDS
>D> AA APOTHECON EQ 125MG BASE/5ML N61410 001 Mar DISC
>A> @ EQ 125MG BASE/5ML N61410 001 Mar DISC
>D> AA EQ 250MG BASE/5ML N61410 002 Mar DISC
>A> @ EQ 250MG BASE/5ML N61410 002 Mar DISC

PHENYTOIN SODIUM

CAPSULE; ORAL
PROMPT PHENYTOIN SODIUM
@ IVAX PHARMS 100MG PROMPT N80259 001 Jan DISC

PINDOLOL

TABLET; ORAL
PINDOLOL
>D> AB SANDOZ 5MG N73608 001 Mar 29, 1993 Mar DISC
>A> @ 5MG N73608 001 Mar 29, 1993 Mar DISC
>D> AB 10MG N73609 001 Mar 29, 1993 Mar DISC

TABLET; ORAL
PINDOLOL
>A> @ SANDOZ 10MG N73609 001 Mar 29, 1993 Mar DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL
POLYETHYLENE GLYCOL 3350
AA GAVIS PHARMS 17GM/SCOOPFUL N77736 001 May 26, 2006 Jan CAHN
@ TEVA PHARMS 17GM/SCOOPFUL N77445 001 May 04, 2006 Jan DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL
GOLYTELY
>D> AA + BRAINTREE 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT N19011 001 Jul 13, 1984 Mar CTEC
>A> + 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT N19011 001 Jul 13, 1984 Mar CTEC

FOR SUSPENSION; ORAL
>D> CO-LAV
>D> AA BOCA PHARMA 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT N73428 001 Jan 28, 1992 Mar DISC
>A> @ 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT N73428 001 Jan 28, 1992 Mar DISC
>D> GO-EVAC
>D> AA BOCA PHARMA 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT N73433 001 Apr 28, 1992 Mar DISC
>A> @ 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT N73433 001 Apr 28, 1992 Mar DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
MICRO-K
@ KV PHARM 8MEQ N18238 001 Feb DISC
MICRO-K 10
@ KV PHARM 10MEQ N18238 002 May 14, 1984 Feb DISC
POTASSIUM CHLORIDE
@ KV PHARM 10MEQ N70980 001 Feb 17, 1987 Feb DISC
WATSON LABS FLORIDA 8MEQ N77419 001 Jun 02, 2008 Feb CTEC
+ 10MEQ N77419 002 Jun 02, 2008 Feb CRLD

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE
AB + WATSON LABS FLORIDA 10MEQ N75604 001 Apr 10, 2002 Jan CRLD

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
PRAZOSIN HYDROCHLORIDE
>D> AB SANDOZ EQ 1MG BASE N72576 001 May 16, 1989 Mar DISC
>A> @ EQ 1MG BASE N72576 001 May 16, 1989 Mar DISC
>D> AB EQ 2MG BASE N72577 001 May 16, 1989 Mar DISC
>A> @ EQ 2MG BASE N72577 001 May 16, 1989 Mar DISC
>D> AB EQ 5MG BASE N72578 001 May 16, 1989 Mar DISC
>A> @ EQ 5MG BASE N72578 001 May 16, 1989 Mar DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
PREDNISOLONE SODIUM PHOSPHATE
AA AMNEAL PHARMS EQ 15MG BASE/5ML N78345 001 Mar 10, 2009 Feb NEWA

PREDNISONE

TABLET; ORAL
PREDNISONE

>D>	AB		SANDOZ	10MG	N89983	001	Jan 12, 1989	Mar	DISC
>A>			@	10MG	N89983	001	Jan 12, 1989	Mar	DISC
>D>	AB			50MG	N89984	001	Jan 12, 1989	Mar	DISC
>A>			@	50MG	N89984	001	Jan 12, 1989	Mar	DISC

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE HYDROCHLORIDE

>A>	AA		SUN PHARM INDS INC	6.25MG/5ML	N40891	001	Mar 13, 2009	Mar	NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
DOLENE

>D>			@ HERITAGE PHARMS INC	65MG	N80530	001		Mar	CMFD
>A>	AA			65MG	N80530	001		Mar	CMFD

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
PROPRANOLOL HYDROCHLORIDE

	AB		UPSHER SMITH	60MG	N78311	001	Mar 06, 2009	Feb	NEWA
	AB			80MG	N78311	002	Mar 06, 2009	Feb	NEWA
	AB			120MG	N78311	003	Mar 06, 2009	Feb	NEWA
	AB			160MG	N78311	004	Mar 06, 2009	Feb	NEWA

TABLET; ORAL
PROPRANOLOL HYDROCHLORIDE

>D>	AB		SANDOZ	10MG	N70663	001	Jun 13, 1986	Mar	DISC
>A>			@	10MG	N70663	001	Jun 13, 1986	Mar	DISC
>D>	AB			20MG	N70664	001	Jun 13, 1986	Mar	DISC
>A>			@	20MG	N70664	001	Jun 13, 1986	Mar	DISC
>D>	AB			40MG	N70665	001	Jun 13, 1986	Mar	DISC
>A>			@	40MG	N70665	001	Jun 13, 1986	Mar	DISC
>D>	AB			60MG	N70666	001	Oct 10, 1986	Mar	DISC
>A>			@	60MG	N70666	001	Oct 10, 1986	Mar	DISC
>D>	AB			80MG	N70667	001	Jun 13, 1986	Mar	DISC
>A>			@	80MG	N70667	001	Jun 13, 1986	Mar	DISC

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL
CORPHED

>D>	AA		SANDOZ	60MG;2.5MG	N88602	001	Apr 11, 1985	Mar	DISC
>A>			@	60MG;2.5MG	N88602	001	Apr 11, 1985	Mar	DISC

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

>D>	AA	+	SANDOZ	60MG;2.5MG	N88193	001	May 17, 1983	Mar	CTEC
>A>		+		60MG;2.5MG	N88193	001	May 17, 1983	Mar	CTEC

RAMIPRIL

CAPSULE; ORAL
RAMIPRIL

	AB		RANBAXY	5MG	N78849	001	Mar 06, 2009	Feb	NEWA
	AB			10MG	N78849	002	Mar 06, 2009	Feb	NEWA

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL
RANITIDINE HYDROCHLORIDE

AA		AMNEAL PHARMS	EQ 15MG BASE/ML	N78312	001	Sep 02, 2008	Feb	CTNA
AA		WOCKHARDT	EQ 15MG BASE/ML	N79212	001	Feb 23, 2009	Feb	NEWA

RISPERIDONE

SOLUTION; ORAL
RISPERDAL

AA	+	ORTHO MCNEIL JANSSEN	1MG/ML	N20588	001	Jun 10, 1996	Jan	CFTG

RISPERIDONE

AA		TEVA	1MG/ML	N76440	001	Jan 30, 2009	Jan	NEWA

TABLET; ORAL
RISPERIDONE

>A>	AB	CADISTA PHARMS	0.25MG	N78828	001	Mar 23, 2009	Mar	NEWA
>A>	AB		0.5MG	N78828	002	Mar 23, 2009	Mar	NEWA
>A>	AB		1MG	N78828	003	Mar 23, 2009	Mar	NEWA
>A>	AB		2MG	N78828	004	Mar 23, 2009	Mar	NEWA
>A>	AB		3MG	N78828	005	Mar 23, 2009	Mar	NEWA
>A>	AB		4MG	N78828	006	Mar 23, 2009	Mar	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERDAL

AB		ORTHO MCNEIL JANSSEN	0.5MG	N21444	001	Apr 02, 2003	Feb	CFTG
AB			2MG	N21444	003	Apr 02, 2003	Feb	CFTG

RISPERIDONE

AB		DR REDDYS LABS LTD	0.5MG	N77328	001	Feb 24, 2009	Feb	NEWA
AB			2MG	N77328	003	Feb 24, 2009	Feb	NEWA

SERTRALINE HYDROCHLORIDE

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

AB		AUSTARPHARMA LLC	EQ 25MG BASE	N78677	001	Mar 04, 2009	Feb	NEWA
AB			EQ 50MG BASE	N78677	002	Mar 04, 2009	Feb	NEWA
AB			EQ 100MG BASE	N78677	003	Mar 04, 2009	Feb	NEWA

SIMVASTATIN

TABLET; ORAL
SIMVASTATIN

>A>	AB	LUPIN	5MG	N78103	005	Apr 14, 2009	Mar	NEWA

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
KALEXATE

>A>	AA	KVK TECH	454GM/BOT	N40905	001	Mar 30, 2009	Mar	NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
NORDITROPIN NORDIFLEX

>A>		NOVO NORDISK INC	30MG/3ML	N21148	007	Mar 10, 2009	Mar	NEWA

STANOZOLOL

TABLET; ORAL
WINSTROL

>A>		@ LUNDBECK INC	2MG	N12885	001	May 14, 1984	Mar	CAHN
>D>		@ OVATION PHARMS	2MG	N12885	001	May 14, 1984	Mar	CAHN

STAVUDINE

FOR SOLUTION; ORAL

STAVUDINE

>A>	AA		CIPLA LTD	1MG/ML	N78030	001	Mar 20, 2009	Mar	NEWA

SUCCIMER

CAPSULE; ORAL

CHEMET

>A>		+	LUNDBECK INC	100MG	N19998	002	Jan 30, 1991	Mar	CAHN
>D>		+	OVATION PHARMS	100MG	N19998	002	Jan 30, 1991	Mar	CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

>A>	AB		PERRIGO CO TENNESSEE	10%	N78649	001	Mar 23, 2009	Mar	NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOPRIM

>D>			@ PAR PHARM	400MG;80MG	N70022	001	Feb 15, 1985	Mar	CMFD
>A>	AB			400MG;80MG	N70022	001	Feb 15, 1985	Mar	CMFD

SULFAMETHOPRIM-DS

>D>			@ PAR PHARM	800MG;160MG	N70032	001	Feb 15, 1985	Mar	CMFD
>A>	AB			800MG;160MG	N70032	001	Feb 15, 1985	Mar	CMFD

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D>	AB		SANDOZ	800MG;160MG	N70890	001	Nov 13, 1986	Mar	DISC
>A>			@	800MG;160MG	N70890	001	Nov 13, 1986	Mar	DISC

SULINDAC

TABLET; ORAL

SULINDAC

>D>	AB		SANDOZ	150MG	N72712	001	Aug 30, 1991	Mar	DISC
>A>			@	150MG	N72712	001	Aug 30, 1991	Mar	DISC
>D>	AB			200MG	N72713	001	Aug 30, 1991	Mar	DISC
>A>			@	200MG	N72713	001	Aug 30, 1991	Mar	DISC

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX

	AP	+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N20080	001	Dec 28, 1992	Jan	CFTG

SUMATRIPTAN SUCCINATE

	AP		APP PHARMS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N79242	001	Mar 02, 2009	Feb	NEWA
	AP		BEDFORD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N79123	001	Feb 06, 2009	Jan	NEWA
	AP		SANDOZ	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N78067	002	Feb 06, 2009	Jan	NEWA
	AP			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78067	001	Feb 06, 2009	Jan	NEWA
	AP		TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N78318	001	Feb 06, 2009	Jan	NEWA
	AP			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78318	002	Feb 06, 2009	Jan	NEWA
	AP			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N77907	001	Feb 06, 2009	Jan	NEWA
	AP		WOCKHARDT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78593	001	Feb 06, 2009	Jan	NEWA

TABLET; ORAL
IMITREX

AB		GLAXOSMITHKLINE	EQ 25MG BASE	N20132	002	Jun 01, 1995	Jan	CFTG
AB			EQ 50MG BASE	N20132	003	Jun 01, 1995	Jan	CFTG
AB	+		EQ 100MG BASE	N20132	001	Jun 01, 1995	Jan	CFTG

SUMATRIPTAN SUCCINATE

AB		RANBAXY	EQ 100MG BASE	N76572	001	Feb 09, 2009	Jan	NEWA
AB		TEVA	EQ 25MG BASE	N76840	001	Feb 09, 2009	Jan	NEWA
AB			EQ 50MG BASE	N76840	002	Feb 09, 2009	Jan	NEWA
AB			EQ 100MG BASE	N76840	003	Feb 09, 2009	Jan	NEWA

SUNITINIB MALATE

CAPSULE; ORAL
SUTENT

>A>		CPPI CV	EQ 37.5MG BASE	N21938	004	Mar 31, 2009	Mar	NEWA

TAMOXIFEN CITRATE

TABLET; ORAL
TAMOXIFEN CITRATE

>D>	AB	ROXANE	EQ 10MG BASE	N76027	001	Feb 20, 2003	Mar	DISC
>A>		@	EQ 10MG BASE	N76027	001	Feb 20, 2003	Mar	DISC
>D>	AB		EQ 20MG BASE	N76027	002	Feb 20, 2003	Mar	DISC
>A>		@	EQ 20MG BASE	N76027	002	Feb 20, 2003	Mar	DISC

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM

>A>		@ NOVEL LABS INC	30MG	N71457	001	Apr 21, 1987	Mar	CAHN
>D>		@ PAR PHARM	30MG	N71457	001	Apr 21, 1987	Mar	CAHN

TEMOZOLOMIDE

POWDER; INTRAVENOUS
TEMODAR

	+	SCHERING	100MG/VIAL	N22277	001	Feb 27, 2009	Feb	NEWA

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL
HYTRIN

>D>	AB	ABBOTT	EQ 1MG BASE	N19057	001	Aug 07, 1987	Mar	CTEC
>A>			EQ 1MG BASE	N19057	001	Aug 07, 1987	Mar	CTEC
>D>	AB	+	EQ 2MG BASE	N19057	002	Aug 07, 1987	Mar	CTEC
>A>		+	EQ 2MG BASE	N19057	002	Aug 07, 1987	Mar	CTEC
>D>	AB		EQ 5MG BASE	N19057	003	Aug 07, 1987	Mar	CTEC
>A>			EQ 5MG BASE	N19057	003	Aug 07, 1987	Mar	CTEC
>D>	AB		EQ 10MG BASE	N19057	004	Aug 07, 1987	Mar	CTEC
>A>			EQ 10MG BASE	N19057	004	Aug 07, 1987	Mar	CTEC

TERAZOSIN HYDROCHLORIDE

>D>	AB	SANDOZ	EQ 1MG BASE	N74315	001	Dec 31, 1998	Mar	DISC
>A>		@	EQ 1MG BASE	N74315	001	Dec 31, 1998	Mar	DISC
>D>	AB		EQ 2MG BASE	N74315	002	Dec 31, 1998	Mar	DISC
>A>		@	EQ 2MG BASE	N74315	002	Dec 31, 1998	Mar	DISC
>D>	AB		EQ 5MG BASE	N74315	003	Dec 31, 1998	Mar	DISC
>A>		@	EQ 5MG BASE	N74315	003	Dec 31, 1998	Mar	DISC
>D>	AB		EQ 10MG BASE	N74315	004	Dec 31, 1998	Mar	DISC
>A>		@	EQ 10MG BASE	N74315	004	Dec 31, 1998	Mar	DISC

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS
FORTEO

			LILLY	0.6MG/2.4ML (0.25MG/ML)	N21318	002	Jun 25, 2008	Feb	NEWA
		+		0.75MG/3ML (0.25MG/ML)	N21318	001	Nov 26, 2002	Feb	CPOT

TESTOSTERONE

GEL; TRANSDERMAL
ANDROGEL

>D>	AB	+	UNIMED PHARMS	1% (5GM/PACKET)	N21015	002	Feb 28, 2000	Mar	CTEC
>D>	AB			1% (2.5GM/PACKET)	N21015	001	Feb 28, 2000	Mar	CTEC
>A>				1% (2.5GM/PACKET)	N21015	001	Feb 28, 2000	Mar	CTEC
>A>	BX	+		1% (5GM/PACKET)	N21015	002	Feb 28, 2000	Mar	CTEC
>D>			TESTOSTERONE						
>D>	AB		WATSON LABS	1% (2.5GM/PACKET)	N76737	001	Jan 27, 2006	Mar	DISC
>D>	AB			1% (5GM/PACKET)	N76737	002	Jan 27, 2006	Mar	DISC
>A>		@		1% (5GM/PACKET)	N76737	002	Jan 27, 2006	Mar	DISC
>A>		@		1% (2.5GM/PACKET)	N76737	001	Jan 27, 2006	Mar	DISC

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELATESTRYL

>A>		@	ENDO PHARMS	200MG/ML	N09165	001		Mar	CAHN
>A>	AO	+		200MG/ML	N09165	003		Mar	CAHN
>D>	AO	+	INDEVUS PHARMS	200MG/ML	N09165	003		Mar	CAHN
>D>		@		200MG/ML	N09165	001		Mar	CAHN

THEOPHYLLINE

SOLUTION; ORAL
THEOPHYLLINE

>D>		+	ROXANE	80MG/15ML	N87449	001	Sep 15, 1983	Mar	DISC
>A>		@		80MG/15ML	N87449	001	Sep 15, 1983	Mar	DISC

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOPTIC

	AT	+	ATON	EQ 0.25% BASE	N18086	001		Feb	CAHN
	AT	+		EQ 0.5% BASE	N18086	002		Feb	CAHN
			TIMOPTIC IN OCUDOSE						
		+	ATON	EQ 0.25% BASE	N19463	001	Nov 05, 1986	Feb	CAHN
		+		EQ 0.5% BASE	N19463	002	Nov 05, 1986	Feb	CAHN

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC
TIMOPTIC-XE

	AB	+	ATON	EQ 0.25% BASE	N20330	001	Nov 04, 1993	Feb	CAHN
	AB	+		EQ 0.5% BASE	N20330	002	Nov 04, 1993	Feb	CAHN

TABLET; ORAL
TIMOLOL MALEATE

>D>	AB		MYLAN	5MG	N72666	001	Jun 08, 1990	Mar	CTEC
>A>				5MG	N72666	001	Jun 08, 1990	Mar	CTEC
>D>	AB			10MG	N72667	001	Jun 08, 1990	Mar	CTEC
>A>				10MG	N72667	001	Jun 08, 1990	Mar	CTEC
>D>	AB	+		20MG	N72668	001	Jun 08, 1990	Mar	CTEC
>A>		+		20MG	N72668	001	Jun 08, 1990	Mar	CTEC
>D>	AB		SANDOZ	5MG	N72550	001	Apr 13, 1989	Mar	DISC
>A>		@		5MG	N72550	001	Apr 13, 1989	Mar	DISC

TABLET; ORAL
TIMOLOL MALEATE

>D>	AB	SANDOZ	10MG	N72551	001	Apr 13, 1989	Mar	DISC
>A>		@	10MG	N72551	001	Apr 13, 1989	Mar	DISC
>D>	AB		20MG	N72552	001	Apr 13, 1989	Mar	DISC
>A>		@	20MG	N72552	001	Apr 13, 1989	Mar	DISC

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

>D>	AB	IVAX PHARMS	100MG	N18894	001	Nov 02, 1984	Mar	CTEC
>A>			100MG	N18894	001	Nov 02, 1984	Mar	CTEC
>D>	AB	SANDOZ	100MG	N71633	001	Dec 09, 1987	Mar	DISC
>A>		@	100MG	N71633	001	Dec 09, 1987	Mar	DISC
>D>	AB		250MG	N70289	001	Mar 13, 1986	Mar	DISC
>A>		@	250MG	N70289	001	Mar 13, 1986	Mar	DISC
>D>	AB		500MG	N70290	001	Mar 13, 1986	Mar	DISC
>A>		@	500MG	N70290	001	Mar 13, 1986	Mar	DISC

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

>D>	AB	SANDOZ	500MG	N86574	001		Mar	DISC
>A>		@	500MG	N86574	001		Mar	DISC

TOLMETIN SODIUM

TABLET; ORAL
TOLMETIN SODIUM

>D>	AB	SANDOZ	EQ 200MG BASE	N73588	001	Jul 31, 1992	Mar	DISC
>A>		@	EQ 200MG BASE	N73588	001	Jul 31, 1992	Mar	DISC
>D>	AB		EQ 600MG BASE	N74002	001	Sep 27, 1993	Mar	DISC
>A>		@	EQ 600MG BASE	N74002	001	Sep 27, 1993	Mar	DISC

TOPIRAMATE

CAPSULE; ORAL
TOPAMAX

>A>	AB	ORTHO MCNEIL JANSSEN	15MG	N20844	001	Oct 26, 1998	Mar	CFTG
>A>	AB	+	25MG	N20844	002	Oct 26, 1998	Mar	CFTG

TOPAMAX SPRINKLE

>D>		ORTHO MCNEIL JANSSEN	15MG	N20844	001	Oct 26, 1998	Mar	CFTG
>D>		+	25MG	N20844	002	Oct 26, 1998	Mar	CFTG

>A> TOPIRAMATE

>A>	AB	BARR	15MG	N76448	001	Apr 15, 2009	Mar	NEWA
>A>	AB		25MG	N76448	002	Apr 15, 2009	Mar	NEWA
>A>	AB	COBALT LABS INC	15MG	N77868	001	Apr 15, 2009	Mar	NEWA
>A>	AB		25MG	N77868	002	Apr 15, 2009	Mar	NEWA
>A>	AB	TEVA	15MG	N76575	001	Apr 17, 2009	Mar	NEWA
>A>	AB		25MG	N76575	002	Apr 17, 2009	Mar	NEWA

TABLET; ORAL
TOPAMAX

>D>		+ ORTHO MCNEIL JANSSEN	25MG	N20505	004	Dec 24, 1996	Mar	CFTG
>A>	AB	+	25MG	N20505	004	Dec 24, 1996	Mar	CFTG
>D>			50MG	N20505	005	Dec 24, 1996	Mar	CFTG
>A>	AB		50MG	N20505	005	Dec 24, 1996	Mar	CFTG
>D>			100MG	N20505	001	Dec 24, 1996	Mar	CFTG
>A>	AB		100MG	N20505	001	Dec 24, 1996	Mar	CFTG

TABLET; ORAL

		TOPAMAX							
>D>		ORTHO MCNEIL JANSSEN	200MG	N20505	002	Dec 24, 1996	Mar		CFTG
>A>	AB		200MG	N20505	002	Dec 24, 1996	Mar		CFTG
		TOPIRAMATE							
>A>	AB	APOTEX INC	25MG	N77733	001	Mar 27, 2009	Mar		NEWA
>A>	AB		50MG	N77733	002	Mar 27, 2009	Mar		NEWA
>A>	AB		100MG	N77733	003	Mar 27, 2009	Mar		NEWA
>A>	AB		200MG	N77733	004	Mar 27, 2009	Mar		NEWA
>A>	AB	AUROBINDO PHARMA	25MG	N78462	001	Mar 27, 2009	Mar		NEWA
>A>	AB		50MG	N78462	002	Mar 27, 2009	Mar		NEWA
>A>	AB		100MG	N78462	003	Mar 27, 2009	Mar		NEWA
>A>	AB		200MG	N78462	004	Mar 27, 2009	Mar		NEWA
>A>	AB	BARR	25MG	N76315	001	Mar 27, 2009	Mar		NEWA
>A>	AB		100MG	N76315	002	Mar 27, 2009	Mar		NEWA
>A>	AB		200MG	N76315	003	Mar 27, 2009	Mar		NEWA
>A>	AB	CIPLA LTD	25MG	N76343	001	Mar 27, 2009	Mar		NEWA
>A>	AB		50MG	N76343	002	Mar 27, 2009	Mar		NEWA
>A>	AB		100MG	N76343	003	Mar 27, 2009	Mar		NEWA
>A>	AB		200MG	N76343	004	Mar 27, 2009	Mar		NEWA
>A>	AB	COBALT LABS INC	25MG	N77643	001	Mar 27, 2009	Mar		NEWA
>A>	AB		50MG	N77643	002	Mar 27, 2009	Mar		NEWA
>A>	AB		100MG	N77643	003	Mar 27, 2009	Mar		NEWA
>A>	AB		200MG	N77643	004	Mar 27, 2009	Mar		NEWA
>A>	AB	GLENMARK GENERICS	25MG	N77627	001	Mar 27, 2009	Mar		NEWA
>A>	AB		50MG	N77627	002	Mar 27, 2009	Mar		NEWA
>A>	AB		100MG	N77627	003	Mar 27, 2009	Mar		NEWA
>A>	AB		200MG	N77627	004	Mar 27, 2009	Mar		NEWA
>A>	AB	INVAGEN PHARMS	25MG	N79162	001	Mar 27, 2009	Mar		NEWA
>A>	AB		50MG	N79162	002	Mar 27, 2009	Mar		NEWA
>A>	AB		100MG	N79162	003	Mar 27, 2009	Mar		NEWA
>A>	AB		200MG	N79162	004	Mar 27, 2009	Mar		NEWA
>A>	AB	MYLAN	25MG	N76314	001	Mar 27, 2009	Mar		NEWA
>A>	AB		50MG	N76314	002	Mar 27, 2009	Mar		NEWA
>A>	AB		100MG	N76314	003	Mar 27, 2009	Mar		NEWA
>A>	AB		200MG	N76314	004	Mar 27, 2009	Mar		NEWA
>A>	AB	PAR PHARM	25MG	N76311	001	Mar 27, 2009	Mar		NEWA
>A>	AB		50MG	N76311	002	Mar 27, 2009	Mar		NEWA
>A>	AB		100MG	N76311	003	Mar 27, 2009	Mar		NEWA
>A>	AB		200MG	N76311	004	Mar 27, 2009	Mar		NEWA
>A>	AB	PLIVA HRVATSKA DOO	25MG	N77905	001	Mar 30, 2009	Mar		NEWA
>A>	AB		50MG	N77905	002	Mar 30, 2009	Mar		NEWA
>A>	AB		100MG	N77905	003	Mar 30, 2009	Mar		NEWA
>A>	AB		200MG	N77905	004	Mar 30, 2009	Mar		NEWA
>A>	AB	RANBAXY	25MG	N76327	001	Mar 27, 2009	Mar		NEWA
>A>	AB		100MG	N76327	002	Mar 27, 2009	Mar		NEWA
>A>	AB		200MG	N76327	003	Mar 27, 2009	Mar		NEWA
>A>	AB	ROXANE	25MG	N76306	001	Mar 27, 2009	Mar		NEWA
>A>	AB		50MG	N76306	002	Mar 27, 2009	Mar		NEWA
>A>	AB		100MG	N76306	003	Mar 27, 2009	Mar		NEWA
>A>	AB		200MG	N76306	004	Mar 27, 2009	Mar		NEWA
>A>	AB	SUN PHARM INDS LTD	25MG	N90278	001	Mar 27, 2009	Mar		NEWA
>A>	AB		50MG	N90278	002	Mar 27, 2009	Mar		NEWA
>A>	AB		100MG	N90278	003	Mar 27, 2009	Mar		NEWA
>A>	AB		200MG	N90278	004	Mar 27, 2009	Mar		NEWA
>A>	AB	TEVA	25MG	N76317	001	Mar 27, 2009	Mar		NEWA

TABLET; ORAL
TOPIRAMATE

>A>	AB		TEVA	50MG	N76317	002	Mar 27, 2009	Mar	NEWA
>A>	AB			100MG	N76317	003	Mar 27, 2009	Mar	NEWA
>A>	AB			200MG	N76317	004	Mar 27, 2009	Mar	NEWA
>A>	AB		TORRENT PHARMS	25MG	N79153	001	Mar 27, 2009	Mar	NEWA
>A>	AB			50MG	N79153	002	Mar 27, 2009	Mar	NEWA
>A>	AB			100MG	N79153	003	Mar 27, 2009	Mar	NEWA
>A>	AB			200MG	N79153	004	Mar 27, 2009	Mar	NEWA
>A>	AB		UNICHEM	25MG	N90162	001	Mar 27, 2009	Mar	NEWA
>A>	AB			50MG	N90162	002	Mar 27, 2009	Mar	NEWA
>A>	AB			100MG	N90162	003	Mar 27, 2009	Mar	NEWA
>A>	AB		ZYDUS PHARMS USA INC	25MG	N78235	001	Mar 27, 2009	Mar	NEWA
>A>	AB			50MG	N78235	002	Mar 27, 2009	Mar	NEWA
>A>	AB			100MG	N78235	003	Mar 27, 2009	Mar	NEWA
>A>	AB			200MG	N78235	004	Mar 27, 2009	Mar	NEWA

TORSEMIDE

TABLET; ORAL
TORSEMIDE

	AB		HETERO DRUGS	5MG	N79234	001	Jan 27, 2009	Jan	NEWA
	AB			10MG	N79234	002	Jan 27, 2009	Jan	NEWA
	AB			20MG	N79234	003	Jan 27, 2009	Jan	NEWA
	AB			100MG	N79234	004	Jan 27, 2009	Jan	NEWA

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
RYZOLT

>D>	BC	+	LABOPHARM CANADA INC	100MG	N21745	001	Dec 30, 2008	Mar	CAHN
>D>	BC			200MG	N21745	002	Dec 30, 2008	Mar	CAHN
>D>	BC			300MG	N21745	003	Dec 30, 2008	Mar	CAHN
>A>	BC	+	PURDUE PHARMA	100MG	N21745	001	Dec 30, 2008	Mar	CAHN
>A>	BC			200MG	N21745	002	Dec 30, 2008	Mar	CAHN
>A>	BC			300MG	N21745	003	Dec 30, 2008	Mar	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
TRAMADOL HYDROCHLORIDE

>D>			@ BIOVAIL	50MG	N21693	001	May 05, 2005	Mar	CAHN
>A>			@ ETHYPHARM NORTH	50MG	N21693	001	May 05, 2005	Mar	CAHN

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HYDROCHLORIDE

	AB		ALVOGEN	50MG	N71636	001	Apr 18, 1988	Feb	CAHN
	AB			100MG	N71514	001	Apr 18, 1988	Feb	CAHN
>D>	AB		SANDOZ	50MG	N72484	001	Apr 30, 1990	Mar	DISC
>A>			@	50MG	N72484	001	Apr 30, 1990	Mar	DISC
>D>	AB			100MG	N72483	001	Apr 30, 1990	Mar	DISC
>A>			@	100MG	N72483	001	Apr 30, 1990	Mar	DISC

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
SANCTURA XR

>A>		+	ENDO PHARMS	60MG	N22103	001	Aug 03, 2007	Mar	CAHN
>D>		+	INDEVUS	60MG	N22103	001	Aug 03, 2007	Mar	CAHN

TABLET; ORAL
SANCTURA

>A>		+	ENDO PHARMS	20MG	N21595	001	May 28, 2004	Mar	CAHN
>D>		+	INDEVUS	20MG	N21595	001	May 28, 2004	Mar	CAHN

TRYPAN BLUE

SOLUTION; OPHTHALMIC
MEMBRANEBLUE

		+	DORC	0.15%	N22278	001	Feb 20, 2009	Feb	NEWA

VALRUBICIN

SOLUTION; INTRAVESICAL
VALSTAR PRESERVATIVE FREE

>A>		+	ENDO PHARMS	40MG/ML	N20892	001	Sep 25, 1998	Mar	CAHN
>D>		+	INDEVUS PHARMS	40MG/ML	N20892	001	Sep 25, 1998	Mar	CAHN

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL
VERAPAMIL HYDROCHLORIDE

>D>	AB		SANDOZ	40MG	N73168	001	Jul 31, 1992	Mar	DISC
>A>			@	40MG	N73168	001	Jul 31, 1992	Mar	DISC
>D>	AB			80MG	N71423	001	May 24, 1988	Mar	DISC
>A>			@	80MG	N71423	001	May 24, 1988	Mar	DISC
>D>	AB			120MG	N71424	001	May 25, 1988	Mar	DISC
>A>			@	120MG	N71424	001	May 25, 1988	Mar	DISC

ZOLPIDEM TARTRATE

>A>			TABLET; SUBLINGUAL						
>A>			EDLUAR						
>A>			OREXO AB	5MG	N21997	001	Mar 13, 2009	Mar	NEWA
>A>		+		10MG	N21997	002	Mar 13, 2009	Mar	NEWA

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

>D>	COREPHARMA	650MG	N76200	001	Mar 19, 2002	Mar	CAHN
>A>	OHM LABS	650MG	N76200	001	Mar 19, 2002	Mar	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	DR REDDYS LABS LTD	5MG/5ML	N90474	002	Mar 30, 2009	Mar	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>A>	DR REDDYS LABS LTD	5MG/5ML	N90474	001	Mar 30, 2009	Mar	NEWA

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	ORCHID HLTHCARE	5MG	N78862	001	Feb 19, 2009	Feb	NEWA
		10MG	N78862	002	Feb 19, 2009	Feb	NEWA

CETIRIZINE HYDROCHLORIDE HIVES

	ORCHID HLTHCARE	5MG	N78862	003	Feb 19, 2009	Feb	NEWA
		10MG	N78862	004	Feb 19, 2009	Feb	NEWA

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

+	RECKITT BENCKISER	EQ 30MG HBR/5ML	N18658	001	Oct 08, 1982	Feb	CAHN

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

>A>	BANNER PHARMACAPS	EQ 200MG FREE ACID AND POTASSIUM SALT	N78682	001	Mar 24, 2009	Mar	NEWA

MIDOL LIQUID GELS

+	BANNER PHARMACAPS	200MG	N21472	001	Oct 18, 2002	Feb	CTNA

TABLET; ORAL

IBUPROFEN

>D>	SANDOZ	200MG	N70733	001	Sep 19, 1986	Mar	DISC
>A>	@	200MG	N70733	001	Sep 19, 1986	Mar	DISC

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

	@ LILLY	50 UNITS/ML;50 UNITS/ML	N20100	001	Apr 29, 1992	Jan	DISC

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

	IVAX PHARMS	EQ 2MG BASE	N76880	001	Feb 18, 2009	Feb	NEWA
		EQ 4MG BASE	N77850	001	Feb 18, 2009	Feb	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE

>D>	SANDOZ	EQ 75MG BASE	N75519	001	Sep 26, 2002	Mar	DISC
>A>	@	EQ 75MG BASE	N75519	001	Sep 26, 2002	Mar	DISC

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2009

NO MARCH 2009 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MARCH 2009 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ADAPALENE; BENZOYL PEROXIDE - EPIDUO							
022320 001	>A>	4717720	May 31, 2010	DS DP			
	>A>	RE34440	May 31, 2010	U-818			
ALBUTEROL SULFATE - VENTOLIN HFA							
020983 001	>A>	6161724	Jan 16, 2018	DP			
	>A>	6161724*PED	Jul 16, 2018				
	>A>	6170717	Dec 23, 2017	DP			
	>A>	6170717*PED	Jun 23, 2018				
	>A>	6431168	Jun 08, 2018	DP			
	>A>	6431168*PED	Dec 08, 2018				
	>A>	6435372	Jan 16, 2018	DP			
	>A>	6435372*PED	Jul 16, 2018				
	>A>	6596260	Aug 10, 2014	DP			
	>A>	6596260*PED	Feb 10, 2015				
	>A>	6938796	Jan 16, 2018	DP			
	>A>	6938796*PED	Jul 16, 2018				
	>A>	6966467	Dec 23, 2017	DP			
	>A>	6966467*PED	Jun 23, 2018				
	>A>	6997349	Jan 16, 2018	DP			
	>A>	6997349*PED	Jul 16, 2018				
	>A>	7107986	Jun 08, 2018	DP			
	>A>	7107986*PED	Dec 06, 2018				
	>A>	7143908	Jan 16, 2018	DP			
	>A>	7143908*PED	Jul 16, 2018				
	>A>	7350676	Aug 24, 2018	DP			
	>A>	7350676*PED	Feb 24, 2019				
	>A>	7500444	Jan 04, 2025	DP			
	>A>	7500444*PED	Jul 04, 2025				
AMIODARONE HYDROCHLORIDE - NEXTERONE							
022325 001		5134127	Jan 23, 2010	DP			
		5376645	Jan 23, 2010	DP			
		6869939	May 04, 2022	DP			
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET							
021540 001	>A>	RE40667	Dec 28, 2010	DS DP U-162			
	>A>	RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET							
021540 002	>A>	RE40667	Dec 28, 2010	DS DP U-162			
	>A>	RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET							
021540 003	>A>	RE40667	Dec 28, 2010	DS DP U-162			
	>A>	RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET							
021540 004	>A>	RE40667	Dec 28, 2010	DS DP U-162			
	>A>	RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET							
021540 005	>A>	RE40667	Dec 28, 2010	DS DP U-162			
	>A>	RE40667*PED	Jun 28, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 006	**>A>** RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 007	**>A>** RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 008	**>A>** RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 009	**>A>** RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 010	**>A>** RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 011	**>A>** RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE - PREVPAC						
050757 001	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	5013743	Feb 12, 2010	U-452			
	5013743*PED	Aug 12, 2010				
	5045321	Sep 03, 2008	DP			
	5045321*PED	Mar 03, 2009				
	5093132	Sep 03, 2008	DP			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP			
	5433959*PED	Mar 03, 2009				
ANASTROZOLE - ARIMIDEX						
020541 001	RE36617	Dec 27, 2009	DS DP U-946			
ARMODAFINIL - NUVIGIL						
021875 002					**>A>** NP	Jun 15, 2010
ARMODAFINIL - NUVIGIL						
021875 005					**>A>** NP	Jun 15, 2010
ATORVASTATIN CALCIUM - LIPITOR						
020702 001	**>A>** RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
ATORVASTATIN CALCIUM - LIPITOR						
020702 002	**>A>** RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
ATORVASTATIN CALCIUM - LIPITOR						
020702 003	**>A>** RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ATORVASTATIN CALCIUM - LIPITOR							
020702 004	>A>	RE40667	Dec 28, 2010	DS DP U-162			
	>A>	RE40667*PED	Jun 28, 2011				
AZITHROMYCIN - AZASITE							
050810 001		5192535	Mar 09, 2010	DP U-709			
		6239113	Mar 31, 2019	U-709			
		6569443	Mar 31, 2019	DP U-709			
		6861411	Nov 25, 2018	U-709			
		7056893	Mar 31, 2019	DP U-709			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA							
050819 001		5733886	Mar 31, 2015	DP U-124			
		6117843	Feb 18, 2012	DP			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - DUAC							
050741 001		5466446	Feb 16, 2014	DS DP			
BETAMETHASONE VALERATE - LUXIQ							
020934 001		7078058	May 24, 2017	DP			
BIMATOPROST - LATISSE							
022369 001						NP	Dec 24, 2011
BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA							
050786 001	>A>	5196205	Mar 23, 2010	U-933			
	>A>	5476669	Mar 23, 2010	U-933			
	>A>	6350468	Dec 14, 2018	U-956			
	>A>	6350468	Dec 14, 2018	U-932			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
021929 001						I-582	Feb 27, 2012
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
021929 002						I-582	Feb 27, 2012
CALCITRIOL - VECTICAL							
022087 001						NDF	Jan 23, 2012
CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE							
020958 001		5075114	May 23, 2010	DP			
		5075114*PED	Nov 23, 2010				
		6814978	Aug 26, 2021	DP			
		6814978*PED	Feb 26, 2022				
CICLESONIDE - ALVESCO							
021658 002						NDF	Jan 10, 2011
						NCE	Oct 20, 2011
CICLESONIDE - ALVESCO							
021658 003						NDF	Jan 10, 2011
						NCE	Oct 20, 2011
CLARITHROMYCIN - BIAXIN XL							
050775 001	>A>	6551616	Jul 15, 2017	U-924			
CLOBETASOL PROPIONATE - OLUX							
021142 001		6126920	Mar 01, 2016	U-484			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CLOPIDOGREL BISULFATE - PLAVIX						
020839 002	4847265	Nov 17, 2011	DS DP			
	6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			
COLESEVELAM HYDROCHLORIDE - WELCHOL						
021141 001	5607669	Jun 10, 2014	U-323			
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014	U-323			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014				
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	U-323			
	5917007*PED	Oct 29, 2014				
	5919832	Jun 10, 2014				
	5919832*PED	Dec 10, 2014				
	6066678	Jun 10, 2014	U-323			
	6066678*PED	Dec 10, 2014				
	6433026	Jun 10, 2014				
	6433026*PED	Dec 10, 2014				
COLESEVELAM HYDROCHLORIDE - WELCHOL						
021176 001	5607669	Jun 10, 2014	U-323		I-553	Jan 18, 2011
	5607669*PED	Dec 10, 2014			PED	Jul 18, 2011
	5679717	Apr 29, 2014	U-323			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS U-323			
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS U-323			
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP U-757			
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022	U-851			
	7229613*PED	Oct 17, 2022				
DEGARELIX ACETATE - DEGARELIX ACETATE						
022201 001	5925730	Apr 11, 2017	DS DP U-943			
DEGARELIX ACETATE - DEGARELIX ACETATE						
022201 002	5925730	Apr 11, 2017	DS DP U-943			
DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST						
050818 001	5149694	Sep 22, 2009	U-953			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXLANSOPRAZOLE - KAPIDEX						
022287 001	5045321	Sep 03, 2008	DP		NP	Jan 30, 2012
	5045321*PED	Mar 03, 2009			PED	Jul 30, 2012
	5093132	Sep 03, 2008	DP U-949			
	5093132	Sep 03, 2008	DP U-950			
	5093132	Sep 03, 2008	DP U-951			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP U-949			
	5433959	Sep 03, 2008	DP U-950			
	5433959	Sep 03, 2008	DP U-951			
	5433959*PED	Mar 03, 2009				
	6462058	Jun 15, 2020	DS DP U-951			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
DEXLANSOPRAZOLE - KAPIDEX						
022287 002	5045321	Sep 03, 2008	DP		NP	Jan 30, 2012
	5045321*PED	Mar 03, 2009			PED	Jul 30, 2012
	5093132	Sep 03, 2008	DP U-949			
	5093132	Sep 03, 2008	DP U-950			
	5093132	Sep 03, 2008	DP U-951			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP U-949			
	5433959	Sep 03, 2008	DP U-950			
	5433959	Sep 03, 2008	DP U-951			
	5433959*PED	Mar 03, 2009				
	6462058	Jun 15, 2020	DS DP U-951			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DILTIAZEM HYDROCHLORIDE - CARDIZEM CD						
020062 005	**>A>** 5286497	May 20, 2011	DP			
	>A> 5439689	Aug 08, 2012	DP U-107			
	>A> 5470584	May 20, 2011	DP			
DIVALPROEX SODIUM - DIVALPROEX SODIUM						
077567 002					PC	Aug 01, 2009
DOXERCALCIFEROL - HECTOROL						
021027 001	**>A>** 5707980	Aug 17, 2010	U-321	Y		
ELTROMBOPAG OLAMINE - PROMACTA						
022291 001	7473686	Jul 24, 2021	DS DP U-930			
ELTROMBOPAG OLAMINE - PROMACTA						
022291 002	7473686	Jul 24, 2021	DS DP U-930			
ESCITALOPRAM OXALATE - LEXAPRO						
021323 001					**>A>** NPP	Mar 19, 2012
ESCITALOPRAM OXALATE - LEXAPRO						
021323 002					**>A>** NPP	Mar 19, 2012
ESCITALOPRAM OXALATE - LEXAPRO						
021323 003					**>A>** NPP	Mar 19, 2012
ESCITALOPRAM OXALATE - LEXAPRO						
021365 001					**>A>** NPP	Mar 19, 2012
ESTRADIOL - ELESTRIN						
021813 001	7470433	Aug 03, 2021	DP			
EVEROLIMUS - AFINITOR						
022334 001	**>A>** 5665772	Sep 09, 2014	DS DP		**>A>** NCE	Mar 30, 2014
	>A> 6004973	Jul 12, 2016	DP			
	>A> 7297703	Dec 06, 2019	DP			
EVEROLIMUS - AFINITOR						
022334 002	**>A>** 5665772	Sep 09, 2014	DS DP		**>A>** NCE	Mar 30, 2014
	>A> 6004973	Jul 12, 2016	DP			
	>A> 7297703	Dec 06, 2019	DP			
FEBUXOSTAT - ULORIC						
021856 001	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
FEBUXOSTAT - ULORIC						
021856 002	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
FLUDARABINE PHOSPHATE - FLUDARABINE PHOSPHATE						
022273 001	7148207	Dec 20, 2022	DP U-944		NDF	Dec 18, 2011
FLUOXETINE HYDROCHLORIDE - PROZAC						
018936 001	**>A>** 6960577	Nov 01, 2017	U-963		**>A>** I-590	Mar 19, 2012
					>A> I-589	Mar 19, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUOXETINE HYDROCHLORIDE - PROZAC						
018936 003	**>A>** 6960577	Nov 01, 2017	U-963		**>A>** I-590	Mar 19, 2012
					>A> I-589	Mar 19, 2012
FLUOXETINE HYDROCHLORIDE - PROZAC						
018936 006	**>A>** 6960577	Nov 01, 2017	U-963		**>A>** I-590	Mar 19, 2012
					>A> I-589	Mar 19, 2012
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
021520 001	**>A>** 6960577	Nov 01, 2017	U-962		**>A>** I-593	Mar 19, 2012
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
021520 002	**>A>** 6960577	Nov 01, 2017	U-962		**>A>** I-593	Mar 19, 2012
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
021520 003	**>A>** 6960577	Nov 01, 2017	U-962		**>A>** I-593	Mar 19, 2012
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
021520 004	**>A>** 6960577	Nov 01, 2017	U-962		**>A>** I-593	Mar 19, 2012
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
021520 005	**>A>** 6960577	Nov 01, 2017	U-962		**>A>** I-593	Mar 19, 2012
FLUTICASONE PROPIONATE - FLOVENT DISKUS 100						
020833 002	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - FLOVENT DISKUS 250						
020833 003	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
FLUTICASONE PROPIONATE - FLOVENT DISKUS 50						
020833 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - FLOVENT HFA						
021433 001	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	>A> 6161724	Jan 16, 2018	DP			
	>A> 6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Jun 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	>A> 6431168	Jun 08, 2018	DP			
	>A> 6431168*PED	Dec 08, 2018				
	>A> 6435372	Jan 16, 2018	DP			
	>A> 6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	>A> 6596260	Aug 10, 2014	DP			
	>A> 6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	>A> 6938796	Jan 16, 2018	DP			
	>A> 6938796*PED	Jul 16, 2018				
	>A> 6966467	Dec 23, 2017	DP			
	>A> 6966467*PED	Jun 23, 2018				
	>A> 6997349	Jan 16, 2018	DP			
	>A> 6997349*PED	Jul 16, 2018				
	>A> 7107986	Jun 08, 2018	DP			
	>A> 7107986*PED	Dec 08, 2019				
	>A> 7143908	Jan 16, 2018	DP			
	>A> 7143908*PED	Jul 16, 2018				
	>A> 7350676	Aug 24, 2018	DP			
	>A> 7350676*PED	Feb 24, 2019				
	>A> 7500444	Jan 04, 2025	DP			
	>A> 7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - FLOVENT HFA						
021433 002	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	>A> 6161724	Jan 16, 2018	DP			
	>A> 6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	>A> 6431168	Jun 08, 2018	DP			
	>A> 6431168*PED	Dec 08, 2018				
	>A> 6435372	Jan 16, 2018	DP			
	>A> 6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	>A> 6596260	Aug 10, 2014	DP			
	>A> 6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	>A> 6938796	Jan 16, 2018	DP			
	>A> 6938796*PED	Jul 16, 2018				
	>A> 6966467	Dec 23, 2017	DP			
	>A> 6966467*PED	Jun 23, 2018				
	>A> 6997349	Jan 16, 2018	DP			
	>A> 6997349*PED	Jul 16, 2018				
	>A> 7107986	Jun 08, 2018	DP			
	>A> 7107986*PED	Dec 08, 2019				
	>A> 7143908	Jan 16, 2018	DP			
	>A> 7143908*PED	Jul 16, 2018				
	>A> 7350676	Aug 24, 2018	DP			
	>A> 7350676*PED	Feb 24, 2019				
	>A> 7500444	Jan 04, 2025	DP			
	>A> 7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - FLOVENT HFA						
021433 003	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015	U-710			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	>A> 6161724	Jan 16, 2018	DP			
	>A> 6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015	U-582			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	>A> 6431168	Jun 08, 2018	DP			
	>A> 6431168*PED	Dec 08, 2018				
	>A> 6435372	Jan 16, 2018	DP			
	>A> 6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015	U-583			
	>A> 6596260	Aug 10, 2014	DP			
	>A> 6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021	U-581			
	>A> 6938796	Jan 16, 2018	DP			
	>A> 6938796*PED	Jul 16, 2018				
	>A> 6966467	Dec 23, 2017	DP			
	>A> 6966467*PED	Jun 23, 2018				
	>A> 6997349	Jan 16, 2018	DP			
	>A> 6997349*PED	Jul 16, 2018				
	>A> 7107986	Jun 08, 2018	DP			
	>A> 7107986*PED	Dec 08, 2019				
	>A> 7143908	Jan 16, 2018	DP			
	>A> 7143908*PED	Jul 16, 2018				
	>A> 7350676	Aug 24, 2018	DP			
	>A> 7350676*PED	Feb 24, 2019				
	>A> 7500444	Jan 04, 2025	DP			
	>A> 7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50						
021077 001	5590645	Mar 01, 2011	DP		**>A>** M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50						
021077 002	5590645	Mar 01, 2011	DP		**>A>** M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50						
021077 003	5590645	Mar 01, 2011	DP		**>A>** M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
021254 001	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	>A> 6161724	Jan 16, 2018	DP			
	>A> 6161724*PED	Jul 16, 2018				
	>A> 6170717	Dec 23, 2017	DP			
	>A> 6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	>A> 6341168	Jun 08, 2018	DP			
	>A> 6341168*PED	Dec 08, 2018				
	>A> 6435372	Jan 16, 2018	DP			
	>A> 6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017				
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015				
	>A> 6596260	Aug 10, 2014	DP			
	>A> 6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-841			
	6743413*PED	Dec 01, 2021	U-841			
	>A> 6938796	Jan 16, 2018	DP			
	>A> 6938796*PED	Jul 16, 2018				
	>A> 6966467	Dec 23, 2017	DP			
	>A> 6966467*PED	Jun 23, 2018				
	>A> 6997349	Jan 16, 2018	DP			
	>A> 6997349*PED	Jul 16, 2018				
	>A> 7107986	Jun 08, 2018	DP			
	>A> 7107986*PED	Dec 08, 2018				
	>A> 7143908	Jan 16, 2018	DP			
	>A> 7143908*PED	Jul 16, 2018				
	>A> 7350676	Aug 24, 2018	DP			
	>A> 7350676*PED	Feb 24, 2019				
	>A> 7500444	Jan 04, 2025	DP			
	>A> 7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
021254 002	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	>A> 6161724	Jan 16, 2018	DP			
	>A> 6161724*PED	Jul 16, 2018				
	>A> 6170717	Dec 23, 2017	DP			
	>A> 6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	>A> 6341168	Jun 08, 2018	DP			
	>A> 6341168*PED	Dec 08, 2018				
	>A> 6435372	Jan 16, 2018	DP			
	>A> 6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	>A> 6596260	Aug 10, 2014	DP			
	>A> 6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-841			
	6743413*PED	Dec 01, 2021	U-841			
	>A> 6938796	Jan 16, 2018	DP			
	>A> 6938796*PED	Jul 16, 2018				
	>A> 6966467	Dec 23, 2017	DP			
	>A> 6966467*PED	Jun 23, 2018				
	>A> 6997349	Jan 16, 2018	DP			
	>A> 6997349*PED	Jul 16, 2018				
	>A> 7107986	Jun 08, 2018	DP			
	>A> 7107986*PED	Dec 08, 2018				
	>A> 7143908	Jan 16, 2018	DP			
	>A> 7143908*PED	Jul 16, 2018				
	>A> 7350676	Aug 24, 2018	DP			
	>A> 7350676*PED	Feb 24, 2019				
	>A> 7500444	Jan 04, 2025	DP			
	>A> 7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
021254 003	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	>A> 6161724	Jan 16, 2018	DP			
	>A> 6161724*PED	Jul 16, 2018				
	>A> 6170717	Dec 23, 2017	DP			
	>A> 6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	>A> 6341168	Jun 08, 2018	DP			
	>A> 6341168*PED	Dec 08, 2018				
	>A> 6435372	Jan 16, 2018	DP			
	>A> 6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	>A> 6596260	Aug 10, 2014	DP			
	>A> 6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-841			
	6743413*PED	Dec 01, 2021	U-841			
	>A> 6938796	Jan 16, 2018	DP			
	>A> 6938796*PED	Jul 16, 2018				
	>A> 6966467	Dec 23, 2017	DP			
	>A> 6966467*PED	Jun 23, 2018				
	>A> 6997349	Jan 16, 2018	DP			
	>A> 6997349*PED	Jul 16, 2018				
	>A> 7107986	Jun 08, 2018	DP			
	>A> 7107986*PED	Dec 08, 2018				
	>A> 7143908	Jan 16, 2018	DP			
	>A> 7143908*PED	Jul 16, 2018				
	>A> 7350676	Aug 24, 2018	DP			
	>A> 7350676*PED	Feb 24, 2019				
	>A> 7500444	Jan 04, 2025	DP			
	>A> 7500444*PED	Jul 04, 2025				
FLUVOXAMINE MALEATE - LUVOX						
021519 001					M-83	Apr 14, 2011
FLUVOXAMINE MALEATE - LUVOX						
021519 002					M-83	Apr 14, 2011
FLUVOXAMINE MALEATE - LUVOX						
021519 003					M-83	Apr 14, 2011
FOSPROPOFOL DISODIUM - LUSEDRA						
022244 001	6204257	Jun 07, 2018	DS DP U-945		NCE	Dec 12, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GADODIAMIDE - OMNISCAN						
022066 002	5362475	Nov 08, 2011	DS			
GLATIRAMER ACETATE - COPAXONE						
020622 001					**>A>** I-594	Feb 27, 2012
GLATIRAMER ACETATE - COPAXONE						
020622 002					**>A>** I-594	Feb 27, 2012
GOSERELIN ACETATE - ZOLADEX						
019726 001	**>A>** 7500964	Feb 26, 2021	DP			
GOSERELIN ACETATE - ZOLADEX						
020578 001	**>A>** 7500964	Feb 26, 2021	DP			
HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT						
021162 003	5591762	Jan 07, 2014	DS DP U-3			
IMATINIB MESYLATE - GLEEVEC						
021588 001					I-583	Dec 19, 2011
IMATINIB MESYLATE - GLEEVEC						
021588 002					I-583	Dec 19, 2011
INSULIN DETEMIR RECOMBINANT - LEVEMIR						
021536 001	5750497	May 16, 2019	DS DP U-668			
INSULIN GLARGINE RECOMBINANT - LANTUS						
021081 001	5656722	Aug 12, 2014	DS DP U-948			
	5656722*PED	Feb 12, 2015				
	>A> 7476652	Jul 23, 2023	DP			
	>A> 7476652*PED	Jan 23, 2024				
INSULIN GLULISINE RECOMBINANT - APIDRA						
021629 002					**>A>** NCE	Apr 16, 2009
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR						
021629 003					**>A>** NPP	Oct 24, 2011
					>A> NCE	Apr 16, 2009
IODIXANOL - VISIPAQUE 270						
020351 001	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
IODIXANOL - VISIPAQUE 270						
020808 001	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
IODIXANOL - VISIPAQUE 320						
020351 002	RE36418	Jul 12, 2011	DP			
IODIXANOL - VISIPAQUE 320						
020808 002	RE36418	Jul 12, 2011	DP			
IXABEPILONE - IXEMPRA KIT						
022065 001	**>A>** 6605599	May 26, 2018	DS DP U-961			
	>A> 6670384	Jan 23, 2022	DP U-960			
	>A> 6670384	Jan 23, 2022	DP U-959			
	>A> 7022330	Jan 23, 2022	DP U-958			
	>A> 7125899	May 26, 2018	DS DP U-957			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IXABEPILONE - IXEMPRA KIT						
022065 002	**>A>** 6605599	May 26, 2018	DS DP U-961			
	>A> 6670384	Jan 23, 2022	DP U-960			
	>A> 6670384	Jan 23, 2022	DP U-959			
	>A> 7022330	Jan 23, 2022	DP U-958			
	>A> 7125899	May 26, 2018	DS DP U-957			
LANSOPRAZOLE - PREVACID						
021428 001	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
LANSOPRAZOLE - PREVACID						
021428 002	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
LANSOPRAZOLE - PREVACID IV						
021566 001	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	7396841	Aug 17, 2021	DP U-947			
	7396841*PED	Feb 17, 2022				
LANSOPRAZOLE; NAPROXEN - PREVACID NAPRAPAC 500 (COPACKAGED)						
021507 004	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	5045321	Sep 03, 2008	DP			
	5045321*PED	Mar 03, 2009				
	5093132	Sep 03, 2008	DP			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP			
	5433959*PED	Mar 03, 2009				
LANTHANUM CARBONATE - FOSRENOL						
021468 001	5968976	Oct 26, 2018	DP U-613			
LANTHANUM CARBONATE - FOSRENOL						
021468 002	5968976	Oct 26, 2018	DP U-613			
LANTHANUM CARBONATE - FOSRENOL						
021468 003	5968976	Oct 26, 2018	DP U-613			
LANTHANUM CARBONATE - FOSRENOL						
021468 004	5968976	Oct 26, 2018	DP U-613			
LEVETIRACETAM - KEPPRA XR						
022285 002					NDF	Sep 12, 2011
LIDOCAINE HYDROCHLORIDE - ZINGO						
022114 001					NPP	Jan 08, 2012
MEMANTINE HYDROCHLORIDE - NAMENDA						
021487 001	**>A>** 5061703	Apr 11, 2015	U-539			
MEMANTINE HYDROCHLORIDE - NAMENDA						
021487 002	**>A>** 5061703	Apr 11, 2015	U-539			
MEMANTINE HYDROCHLORIDE - NAMENDA						
021627 001	**>A>** 5061703	Apr 11, 2015	U-539			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
022256 001	**>A>** 6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	>A> 6992110	Nov 17, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
022256 002	**>A>** 6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	>A> 6992110	Nov 17, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
022256 003	**>A>** 6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	>A> 6992110	Nov 17, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
022256 004	**>A>** 6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	>A> 6992110	Nov 17, 2021	U-882			
MOMETASONE FUROATE - ASMANEX TWISTHALER						
021067 002	**>A>** 5394868	Jun 25, 2012	DP		**>A>** NPP	Feb 01, 2011
	>A> 5394868*PED	Dec 25, 2012				
	>A> 5687710	Nov 18, 2014	DP			
	>A> 5687710*PED	May 18, 2015				
	>A> 5829434	Nov 03, 2015	DP			
	>A> 5829434*PED	May 03, 2016				
	>A> 5889015	Jan 27, 2014	U-645			
	>A> 5889015*PED	Jul 27, 2014				
	>A> 6057307	Jan 27, 2014	DP U-645			
	>A> 6057307*PED	Jul 27, 2014				
	>A> 6240918	Feb 20, 2017	DP			
	>A> 6240918*PED	Aug 20, 2017				
	>A> 6365581	Jan 27, 2014	U-645			
	>A> 6365581*PED	Jul 27, 2014				
	>A> 6503537	Mar 17, 2018	DP			
	>A> 6503537*PED	Sep 17, 2018				
	>A> 6677322	Jan 27, 2014	U-645			
	>A> 6677322*PED	Jul 27, 2014				
	>A> 6949532	Jan 27, 2014	U-645			
	>A> 6949532*PED	Jul 27, 2014				
MORPHINE SULFATE - AVINZA						
021260 005	6066339	Nov 25, 2017	DP			
MORPHINE SULFATE - AVINZA						
021260 006	6066339	Nov 25, 2017	DP			
NITROGLYCERIN - NITROMIST						
021780 001	5869082	Apr 16, 2016	DP			
OLANZAPINE - ZYPREXA						
020592 001	**>A>** 6960577	Nov 01, 2017	U-963		**>A>** I-592	Mar 19, 2012
					>A> I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA						
020592 002	**>A>** 6960577	Nov 01, 2017	U-963		**>A>** I-592	Mar 19, 2012
					>A> I-591	Mar 19, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLANZAPINE - ZYPREXA						
020592 003	**>A>** 6960577	Nov 01, 2017	U-963		**>A>** I-592	Mar 19, 2012
					>A> I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA						
020592 004	**>A>** 6960577	Nov 01, 2017	U-963		**>A>** I-592	Mar 19, 2012
					>A> I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA						
020592 005	**>A>** 6960577	Nov 01, 2017	U-963		**>A>** I-592	Mar 19, 2012
					>A> I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA						
020592 006	**>A>** 6960577	Nov 01, 2017	U-963		**>A>** I-592	Mar 19, 2012
					>A> I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA ZYDIS						
021086 001	**>A>** 6960577	Nov 01, 2017	U-964		**>A>** I-592	Mar 19, 2012
					>A> I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA ZYDIS						
021086 002	**>A>** 6960577	Nov 01, 2017	U-964		**>A>** I-592	Mar 19, 2012
					>A> I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA ZYDIS						
021086 003	**>A>** 6960577	Nov 01, 2017	U-964		**>A>** I-592	Mar 19, 2012
					>A> I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA ZYDIS						
021086 004	**>A>** 6960577	Nov 01, 2017	U-964		**>A>** I-592	Mar 19, 2012
					>A> I-591	Mar 19, 2012
OMEGA-3-ACID ETHYL ESTERS - LOVAZA						
021654 001	**>A>** 5656667	Apr 10, 2017	DS DP U-822			
OXYBUTYNIN CHLORIDE - GELNIQUE						
022204 001	**>A>** 7029694	Apr 26, 2020	DP U-318		NDF	Jan 27, 2012
	>A> 7179483	Apr 26, 2020	U-318			
PALIPERIDONE - INVEGA						
021999 006	**>A>** 5158952	Oct 27, 2009	DP U-90			
PANTOPRAZOLE SODIUM - PROTONIX						
020987 001	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	5997903	Dec 07, 2016				
	5997903*PED	Jun 07, 2017				
PANTOPRAZOLE SODIUM - PROTONIX						
020987 002	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	5997903	Dec 07, 2016				
	5997903*PED	Jun 07, 2017				
PANTOPRAZOLE SODIUM - PROTONIX						
022020 001	4758579	Jul 19, 2010	DS DP U-859			
	4758579*PED	Jan 19, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PANTOPRAZOLE SODIUM - PROTONIX IV						
020988 001	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	6780881	Nov 17, 2021	DP			
	6780881*PED	May 17, 2022				
	7351723	Nov 17, 2021	DP			
	7351723*PED	May 17, 2022				
PRAMLINTIDE ACETATE - SYMLIN						
021332 002	5814600	Sep 29, 2015	U-639			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-637			
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017	U-640			
	6114304	Sep 05, 2017	U-637			
	6608029	Sep 07, 2013	U-641			
	6608029	Sep 07, 2013	U-640			
	6608029	Sep 07, 2013	U-637			
	6610824	Mar 03, 2011	DS			
	7407934	Mar 08, 2011	U-640			
	7407934	Mar 08, 2011	U-637			
PRAMLINTIDE ACETATE - SYMLIN						
021332 003	5814600	Sep 29, 2015	U-639			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-637			
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017	U-640			
	6114304	Sep 05, 2017	U-637			
	6608029	Sep 07, 2013	U-641			
	6608029	Sep 07, 2013	U-640			
	6608029	Sep 07, 2013	U-637			
	6610824	Mar 03, 2011	DS			
	7407934	Mar 08, 2011	U-640			
	7407934	Mar 08, 2011	U-637			
QUETIAPINE FUMARATE - SEROQUEL						
020639 001	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
QUETIAPINE FUMARATE - SEROQUEL						
020639 002	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
QUETIAPINE FUMARATE - SEROQUEL						
020639 003	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
QUETIAPINE FUMARATE - SEROQUEL						
020639 004	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
QUETIAPINE FUMARATE - SEROQUEL						
020639 005	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
QUETIAPINE FUMARATE - SEROQUEL						
020639 006	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
QUETIAPINE FUMARATE - SEROQUEL						
020639 007	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
QUETIAPINE FUMARATE - SEROQUEL XR						
022047 001	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
QUETIAPINE FUMARATE - SEROQUEL XR						
022047 002	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
QUETIAPINE FUMARATE - SEROQUEL XR						
022047 003	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
QUETIAPINE FUMARATE - SEROQUEL XR						
022047 004	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
QUETIAPINE FUMARATE - SEROQUEL XR						
022047 005	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
REMIFENTANIL HYDROCHLORIDE - ULTIVA						
020630 001	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
REMIFENTANIL HYDROCHLORIDE - ULTIVA						
020630 002	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
REMIFENTANIL HYDROCHLORIDE - ULTIVA						
020630 003	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
RISPERIDONE - RISPERIDONE						
076440 001					PC	Jul 29, 2009
SALMETEROL XINAFOATE - SEREVENT						
020692 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
SILODOSIN - RAPAFLO						
022206 001	**>A>** 5780485	Nov 13, 2012	U-902			
SILODOSIN - RAPAFLO						
022206 002	**>A>** 5780485	Nov 13, 2012	U-902			
SINECATECHINS - VEREGEN						
021902 001	**>A>** 5795911	Oct 31, 2020	U-172			
SOMATROPIN RECOMBINANT - HUMATROPE						
019640 001					**>A>** I-585	Mar 12, 2012
SOMATROPIN RECOMBINANT - HUMATROPE						
019640 004	**>A>** 5612315	Mar 18, 2014	DP		**>A>** I-585	Mar 12, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOMATROPIN RECOMBINANT - HUMATROPE						
019640 005	**>A>** 5612315	Mar 18, 2014	DP		**>A>** I-585	Mar 12, 2012
SOMATROPIN RECOMBINANT - HUMATROPE						
019640 006	**>A>** 5612315	Mar 18, 2014	DP		**>A>** I-585	Mar 12, 2012
SOMATROPIN RECOMBINANT - HUMATROPE						
019640 007	**>A>** 5612315	Mar 18, 2014	DP		**>A>** I-585	Mar 12, 2012
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX						
021148 004	**>A>** 5849700	Dec 15, 2015	U-340			
	>A> 5849704	Dec 15, 2015	DP U-340			
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX						
021148 005	**>A>** 5849700	Dec 15, 2015	U-340			
	>A> 5849704	Dec 15, 2015	DP U-340			
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX						
021148 006	**>A>** 5849700	Dec 15, 2015	U-340			
	>A> 5849704	Dec 15, 2015	DP U-340			
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX						
021148 007	**>A>** 5849700	Dec 15, 2015	U-340		**>A>** I-572	Oct 31, 2011
	>A> 5849704	Dec 15, 2015	DP U-340		**>A>** I-551	Sep 20, 2010
					>A> I-536	May 31, 2010
					>A> ODE	May 31, 2014
SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE						
076572 001					PC	Aug 09, 2009
SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE						
076840 003					PC	Aug 09, 2009
SUNITINIB MALATE - SUTENT						
021938 004	**>A>** 6573293	Feb 15, 2021	DS DP U-703		**>A>** NCE	Jan 26, 2011
	>A> 7125905	Feb 15, 2021	DS DP			
	>A> 7211600	Dec 22, 2020	U-883			
TEMOZOLOMIDE - TEMODAR						
022277 001	**>A>** 5260291	Aug 11, 2013	DS DP U-619			
	>A> 5260291*PED	Feb 11, 2014				
	>A> 6987108	Sep 08, 2023	DP			
TIGECYCLINE - TYGACIL						
021821 001					**>A>** I-588	Mar 20, 2012
					>A> I-587	Mar 20, 2012
					>A> I-586	Mar 20, 2012
TOPIRAMATE - TOPAMAX						
020505 001	**>A>** 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPAMAX						
020505 002	**>A>** 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPAMAX						
020505 003	**>A>** 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TOPAMAX						
020505 004	**>A>** 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPAMAX						
020505 005	**>A>** 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPAMAX						
020505 006	**>A>** 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPAMAX						
020844 001	**>A>** 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPAMAX						
020844 002	**>A>** 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPAMAX SPRINKLE						
020844 003	**>A>** 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
TRAMADOL HYDROCHLORIDE - RYZOLT						
021745 001					NP	Dec 30, 2011
TRAMADOL HYDROCHLORIDE - RYZOLT						
021745 002					NP	Dec 30, 2011
TRAMADOL HYDROCHLORIDE - RYZOLT						
021745 003					NP	Dec 30, 2011
TRYPAN BLUE - MEMBRANEBLUE						
022278 001					NCE	Dec 16, 2009
					>A> ODE	Dec 16, 2011
ZOLEDRONIC ACID - RECLAST						
021817 001					**>A>** I-584	Mar 15, 2012
					I-581	Dec 19, 2011
ZOLPIDEM TARTRATE - EDLUAR						
021997 001	**>A>** 6761910	Sep 24, 2018	DP U-674			
ZOLPIDEM TARTRATE - EDLUAR						
021997 002	**>A>** 6761910	Sep 24, 2018	DP U-674			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 29th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm